Title: Systematic review and meta-analysis to estimate the burden of fatal and non-fatal overdose

among people who inject drugs.

Authors: Jalissa Shealey,<sup>1</sup> Eric W. Hall<sup>2</sup>, Therese D. Pigott<sup>1</sup>, Heather Bradley<sup>1</sup>

<sup>1</sup> Department of Population Health Sciences, Georgia State University School of Public Health

<sup>2</sup> Oregon Health Sciences University/Portland State University School of Public Health

#### Abstract

**Background:** People who inject drugs (PWID) have high overdose risk. To assess the burden of drug overdose among PWID in light of opioid epidemic-associated increases in injection drug use (IDU), we estimated rates of non-fatal and fatal overdose among PWID living in Organization for Economic Cooperation and Development (OECD) countries using data from 2010 or later.

*Methods*: PubMed, Psych Info, and Embase databases were systematically searched to identify peerreviewed studies reporting prevalence or rates of recent (past 12 months) fatal or non-fatal overdose events among PWID in OECD countries. Data were extracted and meta-analyzed using random effects models to produce pooled non-fatal and fatal overdose rates.

**Results:** 57 of 13,307 identified reports were included in the review, with 33/57 studies contributing unique data and included in the meta-analysis. Other (24/57) studies presented overlapping data to those included in meta-analysis. The rates of non-fatal and fatal overdose among PWID in OECD countries were 24.74 per 100 person years (PY) (95% CI: 19.86 – 30.83; n=28; I<sup>2</sup>=98.5%) and 0.61 per 100 PY (95% CI: 0.32 – 1.16; n=8; I<sup>2</sup>=93.4%), respectively. The rate of non-fatal overdose was 27.79 in North American countries, 25.71 in Canada, 28.59 in the U.S., and 21.44 in Australia.

**Conclusion:** These findings suggest there is a fatal overdose for every 40 non-fatal overdose events among PWID in OECD countries. The magnitude of overdose burden estimated here underscores the need for expansion of overdose prevention and treatment programs and serves as a baseline estimate for monitoring success of such programs.

#### Introduction

People who inject drugs (PWID) have high risk for overdose, leading to adverse health outcomes including preventable death. It is estimated that, globally, 3.2 million PWID experience at least one non-fatal overdose over the course of a year (Colledge et al., 2019). Compared to people who use substances via other consumption routes, PWID are more likely to experience both non-fatal and fatal overdose due to rapid onset of effects (Caudarella et al., 2016; Mars et al., 2018). Physical consequences of non-fatal overdose can be severe (e.g., cognitive impairment, peripheral neuropathy, paralysis of limbs) and result in lifelong morbidity (Park et al., 2020; Warner-Smith et al., 2002). Consequently, healthcare utilization costs of overdose are substantial. In 2017, the economic burden of overdose and opioid use disorder (OUD) in the U.S. was estimated at \$1.02 trillion, with more than 85% of costs attributable to the value of reduced quality of life and loss of life (Florence et al., 2021). Most concerning, non-fatal overdose events may be followed by subsequent fatal overdose (Caudarella et al., 2016).

Injection drug use (IDU) has likely increased during the past decade due to the trajectory of the U.S. opioid epidemic. While the first wave (1990-2009) of the opioid epidemic involved primarily prescription opioids, the second (2010-2012) and third (2013-) waves are characterized to a large extent by use of primarily injected substances (e.g., heroin, synthetic opioids including fentanyl) (CDC, 2021d). Increasing IDU is difficult to measure directly but is indicated by observed increases in infectious diseases primarily affecting PWID, such as acute hepatitis C virus (CDC, 2021a; Zibbell et al., 2018), infectious endocarditis, and skin and soft tissue infections (Dahlman et al., 2017; Weir et al., 2019). Increases in HIV transmissions among PWID have also been observed in the context of large HIV outbreaks (Alpren et al., 2020; Conrad et al., 2015; Peters et al., 2016). There is an urgent need to understand the burden of non-fatal and fatal overdose in the context of increased IDU.

Monitoring the burden of non-fatal and fatal overdose among PWID is important because overdose events can be prevented with evidence-based interventions. Harm reduction interventions such as syringe services programs (SSPs) and naloxone distribution, as well as medication-assisted treatment (MAT) when appropriate, reduce risk for overdose and other adverse health outcomes among PWID (Adams et al., 2019; Buresh et al., 2020; Ma et al., 2019). Overdose burden estimates can inform resource allocation for prevention programs and are needed for monitoring prevention effectiveness over time.

Given the relative sparsity of data on overdose among PWID, meta-analyses are important tools to produce summary estimates of non-fatal and fatal overdose rates. Here, we use the same metaanalytic methods to estimate non-fatal and fatal overdose rates, facilitating estimation of a fatal to nonfatal overdose ratio that can be used to extrapolate the number of fatal overdoses to a corresponding number of non-fatal events. This meta-analysis also provides updates to several previously conducted, which include data prior to the second and third opioid epidemic waves (pre-2010). For example, Colledge et al. (2019) conducted a global systematic review and meta-analysis of non-fatal overdose among PWID, including studies published during 2002 – 2018 (Colledge et al., 2019). Other related meta-analyses focused more broadly on all-cause mortality among PWID (Mathers et al., 2013) or included people with opioid use disorder regardless of primary route of administration (Bahji et al., 2020; Colledge et al., 2019; Larney et al., 2020; Mathers et al., 2013).

We used data collected in 2010 or later from PWID in Organization for Economic Cooperation and Development (OECD) countries, which have been relatively similarly affected by the opioid epidemic, to estimate overall and country-specific rates of non-fatal and fatal overdose in OECD countries.

#### Methods

#### 2.1 Search Strategy

This systematic review and meta-analysis were conducted in accordance with methods outlined in the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement

guidelines (Page et al., 2021). PubMed, Psych Info, and Embase databases were systematically searched to identify peer-reviewed studies on overdose among PWID published from January 1, 2010 to August 28, 2020. Search terms contained a term related to drug injection (e.g., "PWID", "IDU", "injection") and a term for overdose or death (e.g., "mortality", "fatal"). Complete details of the search terms can be found in Appendix 1.

We imported all search results into Covidence, systematic review management software, and removed duplicate citations. Titles and abstracts were each screened by one team member (J.Y.S., H.B., E.H., and M.G.). Next, the full text manuscripts were independently screened for eligibility by pairs of four researchers (J.Y.S., H.B., E.H., and M.G.), and conflicts were resolved collaboratively or by a third reviewer. Because we were interested in estimating overdose rates among PWID since 2010, we included only overdose data from person who injected within 12 months of data collection. Exclusion criteria were as follows: [1] study population only includes lifetime ("ever") non-medical users of injection drugs, [2] findings only include either prevalence or rates of lifetime ("ever") non-fatal and/or fatal overdose among PWID, [3] study not conducted in an OECD country, [4] study only includes data collected before 2010, [5] study included case reports or overdose descriptions with no denominators, [6] study participants were not human subjects aged 18 years or older, and [7] manuscript not published in English language.

#### 2.2 Data Extraction

Data from all eligible studies were extracted into an excel workbook. Data were double extracted from each study, first by one of three researchers (J.Y.S., J.S., M.G.) and then by one of two researchers (E.S. and H.B.). Conflicts were resolved collaboratively. The following data elements were extracted from each study: the number of participants experiencing a non-fatal or fatal overdose; total years of study follow-up; sample size; recall period (non-fatal overdose); recall period (IDU); range/mean/median/IQR for age of participants; the primary objective of the study; whether or not an

intervention was evaluated as part of the study; study design; geographic location; study name for participants recruited from an established cohort; date of publication; and first author name.

#### 2.2.1 Quality Assessment

Due to the lack of a standardized quality assessment tool for observational studies, we developed our own tool, adapted from two previous reviews (Bahji et al., 2020; Larney et al., 2020), to evaluate the quality of the data presented in the included studies. The tool assessed each study on the following criteria: whether "overdose" event was clearly defined in the questionnaire (for non-fatal overdose only), how participants were recruited (e.g., population-based vs. venue-based), and whether the number of person-years of follow-up were reported. Evaluation of these study quality domains allowed us to assess the representativeness and accuracy of outcome measures provided by the studies included in the analysis.

#### 2.3 Statistical analysis

To have comparable metrics for non-fatal and fatal overdose, we estimated both non-fatal and fatal overdoses in terms of rates per person-years. Non-fatal and fatal overdose rates were calculated by dividing the number of events (i.e., non-fatal or fatal overdoses) by person-years of follow-up in each study. Length of participant follow-up is needed to compute person-years, so for cross-sectional studies, the recall period for non-fatal overdose in the survey instrument was multiplied by sample size to approximate person-years (e.g., 100 people with a 6-month recall period contribute 50 person-years). Reported or approximated person-years were used as denominators for calculating fatal and non-fatal rates, which were log transformed for meta-analysis.

Studies that included overlapping data with other studies meeting inclusion criteria were included in the systematic review but excluded from the meta-analysis; we chose the study with the most inclusive dataset for analysis (see Appendix 6). Notably, thirteen studies that met inclusion criteria reported non-fatal overdose for the same two Canadian cohorts [Vancouver Injection Drug Users Study (VIDUS) and AIDS Care Cohort to Evaluate Exposure to Survival Services (ACCESS)] with varying degrees of temporal overlap. We requested data on non-fatal overdose during 2010 – 2018 from the primary investigators and included those estimates in the meta-analysis in place of the studies with overlapping data.

Pooled rates of non-fatal and fatal overdose among PWID were estimated using a random effects model, given the variation in the included studies' methods and contexts. Estimates of the variance component were computed using restricted maximum likelihood methods. We also conducted subgroup analyses by region and country using random effects models when data were available from at least five studies. Small study effects were examined using both funnel plots and trim and fill when sufficient data were available. We were unable to examine sensitivity of results to study quality because only two studies and the two estimates from VIDUS and ACCESS cohort data met "satisfactory" criteria (e.g., defined overdose, population-based recruitment, reported person years) for all three quality assessment criteria. Heterogeneity in the incidence rates across studies were assessed using the Q-test for the significance of the variance component,  $\tau^2$ , and  $I^2$ . We used R software version 4.0.4 with the metafor (Viechtbauer, 2010) and meta (Balduzzi et al., 2019) packages for the meta-analysis, forest plots, funnel plots and trim and fill.

#### Results

The PRISMA flow chart is shown in Figure 1. We screened 13,307 reports, which resulted in 57 studies included in the systematic review, 33 of which contributed unique data to meta-analyses (Figure 1). In total, there were 35 individual estimates in the meta-analysis for non-fatal overdose because we included investigator-contributed VIDUS and ACCESS cohort data to represent the 13 studies with overlapping data on non-fatal overdose from the same cohorts. These 35 estimates represent an approximately equal number of cross-sectional and longitudinal studies, and the majority were from

Canada (36%), the U.S. (38%), and Australia (14%) (Table 1). There were considerably fewer estimates available for fatal overdose events (n=8) compared to non-fatal events (n=28).

#### 3.1 Non-Fatal Overdose

Twenty-eight estimates contributed to the non-fatal overdose analysis. Across these estimates, there was a mean non-fatal overdose rate of 24.74 per 100 PY (95% CI: 19.86 – 30.83) among PWID living in OECD countries (Table 2). Heterogeneity analysis of the non-fatal rate indicated significant variation across included estimates (Q=1750.91; p-value <0.0001;  $\tau^2$ = 0.34). Using I<sup>2</sup>, it was determined that 98.5% of the heterogeniety was due to variability in the effect sizes as opposed to sampling error. The forest plot of these rates (Figure 2) shows individual estimates are similar to the mean, apart from estimates representing a mean data collection year of 2016 or later, in which case many individual rates are above the mean.

Subgroup analysis (Table 1) yielded a mean rate of non-fatal overdose among PWID living in North American countries of 27.79 per 100 PY (95% CI: 20.68 – 37.35). Of the three countries with adequate data to produce country-level estimates, the U.S. had the highest non-fatal overdose rate (28.59 per 100 PY; 95% CI: 19.46 – 42.02), followed by Canada (25.71 per 100 PY; CI: 17.07 – 38.71), and Australia (21.44 per 100 PY; 95% CI: 13.32 – 34.49).

#### 3.2 Fatal Overdose

The pooled result, based on 8 studies, showed a mean rate of 0.61 fatal overdoses per 100 PY (95% CI: 0.32 – 1.16) among PWID living in OECD countries (Table 2). As with the non-fatal overdose estimates, the fatal overdose estimates also had significant heterogeneity (Q=106.80; p-value <0.0001;  $\tau^2$ = 0.80; I<sup>2</sup>=93.4%) rates (Figure 3). However, the majority of individual study estimates fell close to the mean rate with the exception of one study (Selfridge 2016).

3.3 Study Quality and Risk of Bias

Over half of the analyzed studies (51%) used population-based recruitment to recruit participants. 34% of studies reported PY contributed by study participants, and 27% of non-fatal overdose estimates were derived from studies that provided participants with a definition of what constituted an overdose event. The trim and fill analysis of the non-fatal overdose estimate included twelve additional effect size estimates, decreasing the mean estimate of the non-fatal overdose to 15.93 per 100 PY (95% CI: 12.15 – 20.89). Given that only eight studies contributed to the fatal overdose estimate, examination of small study effects using a funnel plot was not possible. The trim and fill analysis did not add any effect size estimates to the pooled estimate.

#### Discussion

In this systematic review and meta-analysis, we estimated rates of 24.7 non-fatal and 0.6 fatal overdoses per 100 PY among PWID in OECD countries. To our knowledge, this is the first review to estimate rates of both fatal and nonfatal overdose among PWID using comparable methodology. Non-fatal overdose is a strong predictor of fatal overdose (Caudarella et al., 2016), and based on these findings, we estimate one fatal overdose for every 40 non-fatal overdose events among PWID. This ratio provides compelling evidence for the need to prevent not only fatal overdoses, but all overdose events due to the high likelihood of death conditional on overdose (Olfson et al., 2018). This ratio can also be applied to externally derived estimates of either non-fatal or fatal overdose in order to fill data gaps. For example, as data on fatal overdose among PWID become more readily available through surveillance, the ratio can be used to extrapolate the number of fatal overdoses to the corresponding number of non-fatal events (CDC, 2021c; Hall et al., 2021). Additionally, in settings with adequate data on non-fatal overdose burden, the ratio can facilitate evaluation of overdose mortality prevention strategies by allowing assessment of expected versus observed overdose deaths at a given level of non-fatal overdose.

The estimates presented in this review have additional important applications. First, these results can provide comparison estimates to non-fatal and fatal overdose rates among non-injecting substance users, which can be used to understand excess burden of overdose associated with injection. Second, they provide pre-COVID-19 pandemic estimates that can be used as a comparison point for overdose rates among PWID that have likely increased during the pandemic. Quantifying the change in overdose that has occurred during the pandemic is a necessary first step to understanding driving factors (e.g. changes in consumption behaviors, access to harm reduction services) and subsequently intervening on these overdose outcomes (Croxford et al., 2021; Gleason et al., 2021). Third, they can be used to inform resource allocation needs for overdose prevention services such as (SSPs and naloxone distribution, as well as substance use treatment services such as opioid agonist therapy (OAT). Last, these estimates provide a useful baseline estimate for evaluation and effectiveness studies, and implementation models of overdose prevention strategies for PWID.

Harm reduction and substance use treatment services are evidence-based, effective strategies for preventing overdose events among PWID and other people with substance use disorder. The substantial burden of non-fatal and fatal overdose we estimated indicates considerable improvements are needed in provision of harm reduction services, such as SSPs and naloxone distribution, as well as substance use treatment including MAT. Naloxone administration programs have had a notable impact on reducing the burden of overdose among PWID, and a systematic review on take-home naloxone (THN) indicated 95% of naloxone administrations were successful in reversing overdose events (Mcdonald and Strang, 2016). SSPs are also highly effective not only in reducing injection-related infections (by providing sterile injection equipment) but also in increasing naloxone provision and linking PWID to substance use counseling and treatment (Hochstatter et al., 2020; Lambdin et al., 2020). When indicated, OAT can reduce the burden of overdose, as well as other adverse consequences of substance use, among PWID by reducing frequency of substance use (Pearce et al., 2020; Wakeman et al., 2020). Scale-up of overdose prevention and treatment programs, particularly in the U.S., has great potential to save lives, prevent long-term morbidity, and save healthcare costs (Banerjee and Wright, 2020; Saloner et al., 2018).

Very little previous work has been done to estimate non-fatal or fatal overdose rates across recent studies, but there are several relevant comparison points for our estimates. Larney et al. (2020) estimated an all-cause mortality rate of 2.7 per 100 PY among opioid-injecting cohorts globally and a drug-related mortality rate of 0.5 per 100 PY among non-injecting and injecting non-medical users of opioids (Larney et al., 2020). Studies included in this meta-analysis covered a similar time period (2009 – 2019) to our study, but there was no pooled estimate of drug-related mortality among PWID, either globally or by region. Using studies from 2002 – 2017, Colledge et al. (2019) estimated 20.5% of PWID globally experienced at least one overdose in a 12-month period, while 23.0%, 15.6%, and 11.9% experienced at least one overdose per 12 months in North America, Western Europe, and Australia, respectively. Additionally, older systematic reviews and meta-analyses can be used for comparison points over time. Martins et al. (2015) indicated 18.8% of substance users globally, including PWID and others, experienced non-fatal overdose in the past 12 months with fatal overdose rates ranging widely from 0.04 – 46.6 per 100,000 PY (studies published 1980 – 2013) (Martins et al., 2015). Last, Mathers et al. (2013) estimated a global all-cause mortality rate of 0.6 per 100 PY among PWID globally, but this estimate was not presented regionally or by country (Mathers et al., 2013). Although these studies provide important context, simultaneous differences by time, place, and types of substance users (e.g., injecting vs. non-injecting) included make it difficult to directly compare these estimates to our results.

#### 4.1 Limitations of The Data

Our systematic review resulted in many studies related to overdose, however studies specific to PWID, or presenting stratified PWID-specific estimates, were limited. Even fewer reported recent overdose among PWID, with many studies including only a lifetime measurement for overdose. These

studies were not included because the time periods in which overdose(s) were experienced were unknown. Other studies that focused on PWID were limited to opioid injection, despite recent increases in stimulant injection (Serota et al., 2020). Furthermore, a limitation of studies that did focus broadly on overdose among PWID was the common use of self-report data to measure non-fatal overdose (versus a medically verified event), which may be affected by social desirability bias or an inconsistent understanding of what constitutes an overdose event across participants and interviewers. Resulting information bias would likely lead to an underestimate of non-fatal overdose events.

Most countries included in our review, including the U.S., did not have enough studies to facilitate robust, country-specific meta-analyzed estimates for non-fatal and fatal overdose among PWID. This is problematic because recent data indicate overdose mortality among PWID in the U.S. has increased substantially over time (Hall et al., 2021; Sun et al., 2021). Of the studies included in our review, few included data from the last 2 – 3 years. As a result, we needed to include studies with follow-up periods beginning before recent waves of opioid epidemic (pre-2010) for stable estimates. Even fewer included studies represented rural areas, which have been heavily affected by the U.S. opioid epidemic (Rigg et al., 2018).

#### 4.2. Limitations of the Analysis

This review and meta-analysis is also subject to several limitations. First, included studies were limited to peer-reviewed sources, which may have introduced publication bias into our results. However, due to the general dearth of data in this area, we expect most relevant data would be published in the peer-reviewed literature. Second, due to between study variation in risk population and geographic location, we observed a high degree of heterogeneity across study-specific estimates. This heterogeneity may be caused by changes in IDU and substance types over time, as well as country-level differences in response to the epidemic. Last, to produce comparable non-fatal and fatal overdose estimates, we expressed non-fatal overdose as a rate as opposed to a proportion. Where possible, we extracted rates of non-fatal overdose, but many estimates of non-fatal overdose came from crosssectional survey surveys that asked participants to report any (one or more) overdose in the past year. For these studies, we approximated PY using the recall period and sample size. Doing so may have underestimated non-fatal overdose rate due to an inability to account for multiple overdose events during a given time period.

In recent years, there has been notable investment in the improvement of surveillance data for overdose among PWID in the United States. The primary surveillance source for monitoring non-fatal overdose among PWID is the National HIV Behavioral Surveillance (NHBS) system. NHBS began collecting data on non-fatal overdose in 2018 (CDC, 2020). Additionally, in 2019 CDC invested \$12.8 million to improve the timeliness of reporting non-fatal overdose events from emergency medical services and departments (CDC, 2021b). A portion of this investment was allocated to the State Unintentional Drug Overdose Reporting System (SUDORS) to increase the speed and comprehensiveness of reporting fatal overdose events to a national surveillance system (CDC, 2021b). Although these investments improve our ability to monitor unintentional drug overdoses, research studies continue to play an important role in overdose measurement over time. Longstanding cohort studies of PWID are especially helpful for overdose monitoring, but most of these are focused in urban areas. Additional cohort studies across diverse geographic locations, including rural communities, are needed for a more comprehensive understanding of overdose burden. Additionally, mechanisms for harmonizing data elements and sharing data across ongoing cohort studies can help produce more standardized data and shorten the lag time between study completion, publication and use of data to inform timely public health programs.

#### Conclusion

In this systematic review and meta-analysis, we report updated estimates of fatal and non-fatal overdose rates among PWID that suggest, in OECD countries similarly affected by the opioid epidemic,

there is 1 fatal drug overdose for every 40 non-fatal overdoses. The estimated magnitude of overdose burden reported here underscores the need for expansion of overdose prevention and treatment programs and serves as a baseline estimate for monitoring success of such programs. Given likely increases in IDU and known increases in fatal drug overdose during the COVID-19 pandemic, expansion of surveillance and research on overdose and related health outcomes among PWID should be prioritized.

Acknowledgements: The authors acknowledge Marcus Goff and Jonathan Standish for assistance with data extraction. The authors acknowledge funding for this work from the Centers for Disease Control and Prevention, National Center for National Center for HIV, Viral Hepatitis, STD, and TB Prevention (U38PS004650) and the National Institutes of Health, National Institute on Drug Abuse

#### References

Adams, M., An, Q., Broz, D., Burnett, J., Wejnert, C., Paz-Bailey, G., 2019. Distributive Syringe Sharing and Use of Syringe Services Programs (SSPs) Among Persons Who Inject Drugs. AIDS and Behavior 23(12), 3306-3314.

Åhman, A., Jerkeman, A., Blomé, M.A., Björkman, P., Håkansson, A., 2018. Mortality and causes of death among people who inject amphetamine: A long-term follow-up cohort study from a needle exchange program in Sweden. Drug Alcohol Depend 188, 274-280.

Al-Tayyib, A., Koester, S., Langegger, S., Raville, L., 2017. Heroin and Methamphetamine Injection: An Emerging Drug Use Pattern. Subst Use Misuse 52(8), 1051-1058.

Al-Tayyib, A.A., Koester, S., Riggs, P., 2017. Prescription opioids prior to injection drug use: Comparisons and public health implications. Addict Behav 65, 224-228.

Allen, S.T., White, R.H., O'Rourke, A., Grieb, S.M., Kilkenny, M.E., Sherman, S.G., 2019. Take-home naloxone possession among people who inject drugs in rural West Virginia. Drug Alcohol Depend 204, 107581.

Alpren, C., Dawson, E.L., John, B., Cranston, K., Panneer, N., Fukuda, H.D., Roosevelt, K., Klevens, R.M., Bryant, J., Peters, P.J., Lyss, S.B., Switzer, W.M., Burrage, A., Murray, A., Agnew-Brune, C., Stiles, T., Mcclung, P., Campbell, E.M., Breen, C., Randall, L.M., Dasgupta, S., Onofrey, S., Bixler, D., Hampton, K., Jaeger, J.L., Hsu, K.K., Adih, W., Callis, B., Goldman, L.R., Danner, S.P., Jia, H., Tumpney, M., Board, A., Brown, C., Demaria, A., Buchacz, K., 2020. Opioid Use Fueling HIV Transmission in an Urban Setting: An Outbreak of HIV Infection Among People Who Inject Drugs—Massachusetts, 2015–2018. American Journal of Public Health 110(1), 37-44.

Bahji, A., Cheng, B., Gray, S., Stuart, H., 2020. Mortality Among People With Opioid Use Disorder: A Systematic Review and Meta-analysis. Journal of Addiction Medicine 14(4), e118-e132.

Balduzzi, S., Rücker, G., Schwarzer, G., 2019. How to perform a meta-analysis with R: a practical tutorial. Evidence Based Mental Health 22(4), 153-160.

Banerjee, S., Wright, M.-D., 2020. Injectable Opioid Agonist Treatment for Patients with Opioid Dependence: A Review of Clinical and Cost-Effectiveness. Canadian Agency for Drugs and Technologies in Health, Ottawa (ON).

Betts, K.S., McIlwraith, F., Dietze, P., Whittaker, E., Burns, L., Cogger, S., Alati, R., 2015. Can differences in the type, nature or amount of polysubstance use explain the increased risk of non-fatal overdose among psychologically distressed people who inject drugs? Drug Alcohol Depend 154, 76-84.

Bluthenthal, R.N., Simpson, K., Ceasar, R.C., Zhao, J., Wenger, L., Kral, A.H., 2020. Opioid withdrawal symptoms, frequency, and pain characteristics as correlates of health risk among people who inject drugs. Drug Alcohol Depend 211, 107932.

Buresh, M., Gicquelais, R.E., Astemborski, J., Kirk, G.D., Mehta, S.H., Genberg, B.L., 2020. Fatal overdose prevention and experience with naloxone: A cross-sectional study from a community-based cohort of people who inject drugs in Baltimore, Maryland. PLoS One 15(3), e0230127.

Calvo, M., MacFarlane, J., Zaccaro, H., Curtis, M., Cabán, M., Favaro, J., Passannante, M.R., Frost, T., 2017. Young people who use drugs engaged in harm reduction programs in New York City: Overdose and other risks. Drug Alcohol Depend 178, 106-114.

Carlson, R.G., Daniulaityte, R., Silverstein, S.M., Nahhas, R.W., Martins, S.S., 2020. Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose? Int J Drug Policy 79, 102722.

Caudarella, A., Dong, H., Milloy, M.J., Kerr, T., Wood, E., Hayashi, K., 2016. Non-fatal overdose as a risk factor for subsequent fatal overdose among people who inject drugs. Drug Alcohol Depend 162, 51-55.

CDC, 2020. HIV Infection Risk, Prevention, and Testing Behaviors among Persons Who Inject Drugs— National HIV Behavioral Surveillance: Injection Drug Use, 23 U.S. Cities, 2018. HIV Surveillance Special Report 24.

CDC, 2021a. 2019 Viral Hepatitis Surveillance Report.

CDC, 2021b. Enhanced State Opioid Overdose Surveillance.

CDC, 2021c. Opioid Data Analysis and Resources. CDC's Response to the Opioid Overdose Epidemic.

CDC, 2021d. Overdose Waves. <u>https://www.cdc.gov/opioids/data/analysis-resources.html</u>.

Cedarbaum, E.R., Banta-Green, C.J., 2016. Health behaviors of young adult heroin injectors in the Seattle area. Drug and Alcohol Dependence 158, 102-109.

Colledge, S., Peacock, A., Leung, J., Larney, S., Grebely, J., Hickman, M., Cunningham, E., Trickey, A., Stone, J., Vickerman, P., Degenhardt, L., 2019. The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis. The International journal on drug policy.

Conrad, C., Bradley, H.M., Broz, D., Buddha, S., Chapman, E.L., Galang, R.R., Hillman, D., Hon, J., Hoover, K.W., Patel, M.R., Perez, A., Peters, P.J., Pontones, P., Roseberry, J.C., Sandoval, M., Shields, J., Walthall, J., Waterhouse, D., Weidle, P.J., Wu, H., Duwve, J.M., 2015. Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone - Indiana, 2015. U.S. Center for Disease Control, Atlanta, United States, pp. 443-444.

Croxford, S., Emanuel, E., Ibitoye, A., Njoroge, J., Edmundson, C., Bardsley, M., Heinsbroek, E., Hope, V., Phipps, E., 2021. Preliminary indications of the burden of COVID-19 among people who inject drugs in England and Northern Ireland and the impact on access to health and harm reduction services. Public Health 192, 8-11.

Dahlman, D., Håkansson, A., Kral, A.H., Wenger, L., Ball, E.L., Novak, S.P., 2017. Behavioral characteristics and injection practices associated with skin and soft tissue infections among people who inject drugs: A community-based observational study. Substance Abuse 38(1), 105-112.

Davis, J.M., Suleta, K., Corsi, K.F., Booth, R.E., 2017. A Hazard Analysis of Risk Factors of Mortality in Individuals Who Inject Drugs in Denver CO. AIDS Behav 21(4), 1044-1053.

Escudero, D.J., Marshall, B.D., Kerr, T., Hayashi, K., Feng, C., Guillemi, S.A., Hogg, R.S., Montaner, J., Wood, E., Milloy, M.J., 2016. No association between HIV status and risk of non-fatal overdose among people who inject drugs in Vancouver, Canada. Addict Behav 60, 8-12.

Fairbairn, N., Hayashi, K., Milloy, M.J., Nolan, S., Nguyen, P., Wood, E., Kerr, T., 2016. Hazardous Alcohol Use Associated with Increased Sexual Risk Behaviors Among People Who Inject Drugs. Alcohol Clin Exp Res 40(11), 2394-2400.

Florence, C., Luo, F., Rice, K., 2021. The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. Drug and Alcohol Dependence 218, 108350.

Folch, C., Lorente, N., Majó, X., Parés-Badell, O., Roca, X., Brugal, T., Roux, P., Carrieri, P., Colom, J., Casabona, J., 2018. Drug consumption rooms in Catalonia: A comprehensive evaluation of social, health and harm reduction benefits. Int J Drug Policy 62, 24-29.

Geddes, L., Iversen, J., Memedovic, S., Maher, L., 2018. Intravenous fentanyl use among people who inject drugs in Australia. Drug Alcohol Rev 37 Suppl 1, S314-S322.

Gleason, E., Nolan, N.S., Marks, L.R., Habrock, T., Liang, S.Y., Durkin, M.J., 2021. Barriers to Care Experienced by Patients Who Inject Drugs During the COVID-19 Pandemic: A Qualitative Analysis. Journal of Addiction Medicine.

Hall, E.W., Rosenberg, E.S., Jones, C.M., Asher, A., Valverde, E., Bradley, H.M., 2021. Estimated number of injection-involved drug overdose deaths, United States, 2000 – 2018. Under review at Drug Alcohol Dependence.

Hayashi, K., Dong, H., Kerr, T., Dobrer, S., Guillemi, S., Barrios, R., Montaner, J.S.G., Wood, E., Milloy, M.J., 2017. Declining Mortality Rates in HIV-Infected People Who Inject Drugs During a Seek-and-Treat Initiative in Vancouver, Canada, 1996-2014: A Prospective Cohort Study. J Infect Dis 217(1), 64-68. Hayashi, K., Dong, H., Marshall, B.D., Milloy, M.J., Montaner, J.S., Wood, E., Kerr, T., 2016. Sex-Based Differences in Rates, Causes, and Predictors of Death Among Injection Drug Users in Vancouver, Canada. Am J Epidemiol 183(6), 544-552.

Hayashi, K., Milloy, M.J., Lysyshyn, M., DeBeck, K., Nosova, E., Wood, E., Kerr, T., 2018. Substance use patterns associated with recent exposure to fentanyl among people who inject drugs in Vancouver, Canada: A cross-sectional urine toxicology screening study. Drug Alcohol Depend 183, 1-6.

Hochstatter, K.R., Hull, S.J., Sethi, A.K., Burns, M.E., Mundt, M.P., Westergaard, R.P., 2020. Promoting Safe Injection Practices, Substance Use Reduction, Hepatitis C Testing, and Overdose Prevention Among Syringe Service Program Clients Using a Computer-Tailored Intervention: Pilot Randomized Controlled Trial. Journal of Medical Internet Research 22(9), e19703.

Horyniak, D., Dietze, P., Degenhardt, L., Higgs, P., McIlwraith, F., Alati, R., Bruno, R., Lenton, S., Burns, L., 2013. The relationship between age and risky injecting behaviours among a sample of Australian people who inject drugs. Drug Alcohol Depend 132(3), 541-546.

Horyniak, D., Higgs, P., Jenkinson, R., Degenhardt, L., Stoové, M., Kerr, T., Hickman, M., Aitken, C., Dietze, P., 2013. Establishing the Melbourne Injecting Drug User Cohort Study (MIX): rationale, methods, and baseline and twelve-month follow-up results. Harm Reduction Journal 10, 11.

Hunter, K., Park, J.N., Allen, S.T., Chaulk, P., Frost, T., Weir, B.W., Sherman, S.G., 2018. Safe and unsafe spaces: Non-fatal overdose, arrest, and receptive syringe sharing among people who inject drugs in public and semi-public spaces in Baltimore City. Int J Drug Policy 57, 25-31.

Ickowicz, S., Grant, C., Nosova, E., Boyd, J., Brar, R., Milloy, M.J., Hayashi, K., Nolan, S., 2020. Factors Associated with the Use of Supervised Consumption Facilities among Women Who Inject Drugs in a Canadian Setting. J Addict Med.

Ickowicz, S., Wood, E., Dong, H., Nguyen, P., Small, W., Kerr, T., Montaner, J.S.G., Milloy, M.J., 2017. Association between public injecting and drug-related harm among HIV-positive people who use injection drugs in a Canadian setting: A longitudinal analysis. Drug Alcohol Depend 180, 33-38. Iversen, J., Dertadian, G., Geddes, L., Maher, L., 2017. High risk injecting behaviour among people who inject pharmaceutical opioids in Australia. Int J Drug Policy 42, 1-6.

Kennedy, M.C., Hayashi, K., Milloy, M.J., Wood, E., Kerr, T., 2019. Supervised injection facility use and allcause mortality among people who inject drugs in Vancouver, Canada: A cohort study. PLoS Med 16(11), e1002964.

Kimber, J., Stoové, M., Maher, L., 2019. Mortality among people who inject drugs: Ten-year follow-up of the hepatitis C virus cohort. Drug Alcohol Rev 38(3), 270-273.

Lake, S., Hayashi, K., Buxton, J., Milloy, M.J., Dong, H., Wood, E., Montaner, J., Kerr, T., 2015a. The effect of prescription opioid injection on the risk of non-fatal overdose among people who inject drugs. Drug Alcohol Depend 156, 297-303.

Lake, S., Hayashi, K., Milloy, M.J., Wood, E., Dong, H., Montaner, J., Kerr, T., 2015b. Associations between childhood trauma and non-fatal overdose among people who inject drugs. Addict Behav 43, 83-88.

Lake, S., Wood, E., Buxton, J., Dong, H., Montaner, J., Kerr, T., 2015c. Prescription opioid use and non-fatal overdose in a cohort of injection drug users. Am J Drug Alcohol Abuse 41(3), 257-263.

Lambdin, B.H., Bluthenthal, R.N., Wenger, L.D., Wheeler, E., Garner, B., Lakosky, P., Kral, A.H., 2020. Overdose Education and Naloxone Distribution Within Syringe Service Programs — United States, 2019. MMWR. Morbidity and Mortality Weekly Report 69(33), 1117-1121.

Larney, S., Tran, L.T., Leung, J., Santo, T., Santomauro, D., Hickman, M., Peacock, A., Stockings, E., Degenhardt, L., 2020. All-Cause and Cause-Specific Mortality Among People Using Extramedical Opioids. JAMA Psychiatry 77(5), 493.

Latkin, C.A., Dayton, L., Davey-Rothwell, M.A., Tobin, K.E., 2019. Fentanyl and Drug Overdose: Perceptions of Fentanyl Risk, Overdose Risk Behaviors, and Opportunities for Intervention among People who use Opioids in Baltimore, USA. Subst Use Misuse 54(6), 998-1006.

Ma, J., Bao, Y.-P., Wang, R.-J., Su, M.-F., Liu, M.-X., Li, J.-Q., Degenhardt, L., Farrell, M., Blow, F.C., Ilgen, M., Shi, J., Lu, L., 2019. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry 24(12), 1868-1883.

Mars, S.G., Ondocsin, J., Ciccarone, D., 2018. Toots, tastes and tester shots: user accounts of drug sampling methods for gauging heroin potency. Harm Reduction Journal 15(1).

Martins, S.S., Sampson, L., Cerdá, M., Galea, S., 2015. Worldwide Prevalence and Trends in Unintentional Drug Overdose: A Systematic Review of the Literature. American Journal of Public Health 105(11), e29-e49.

Mathers, M., Bradley, Degenhardt, L., Bucello, C., Lemon, J., Wiessing, L., Hickman, M., 2013. Mortality among people who inject drugs: a systematic review and meta-analysis. Bulletin of the World Health Organization 91(2), 102-123.

McCrae, K., Hayashi, K., Bardwell, G., Nosova, E., Milloy, M.J., Wood, E., Ti, L., 2020. The effect of injecting alone on the use of drug checking services among people who inject drugs. Int J Drug Policy 79, 102756.

Mcdonald, R., Strang, J., 2016. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction 111(7), 1177-1187.

Meacham, M.C., Roesch, S.C., Strathdee, S.A., Lindsay, S., Gonzalez-Zuniga, P., Gaines, T.L., 2018. Latent classes of polydrug and polyroute use and associations with human immunodeficiency virus risk behaviours and overdose among people who inject drugs in Tijuana, Baja California, Mexico. Drug Alcohol Rev 37(1), 128-136.

Nambiar, D., Agius, P.A., Stoové, M., Hickman, M., Dietze, P., 2015. Mortality in the Melbourne injecting drug user cohort study (MIX). Harm Reduct J 12, 55.

O'Halloran, C., Cullen, K., Njoroge, J., Jessop, L., Smith, J., Hope, V., Ncube, F., 2017. The extent of and factors associated with self-reported overdose and self-reported receipt of naloxone among people who inject drugs (PWID) in England, Wales and Northern Ireland. Int J Drug Policy 46, 34-40.

O'Rourke, A., White, R.H., Park, J.N., Rodriguez, K., Kilkenny, M.E., Sherman, S.G., Allen, S.T., 2019. Acceptability of safe drug consumption spaces among people who inject drugs in rural West Virginia. Harm Reduct J 16(1), 51.

Oh, H., Kim, K., Miller, D., Veloso, D., Lin, J., McFarland, W., 2020. Fentanyl self-testing in a communitybased sample of people who inject drugs, San Francisco. Int J Drug Policy 82, 102787.

Olfson, M., Wall, M., Wang, S., Crystal, S., Blanco, C., 2018. Risks of fatal opioid overdose during the first year following nonfatal overdose. Drug and Alcohol Dependence 190, 112-119.

Page, M.J., Mckenzie, J.E., Bossuyt, P.M., Boutron, I., Hoffmann, T.C., Mulrow, C.D., Shamseer, L., Tetzlaff, J.M., Akl, E.A., Brennan, S.E., Chou, R., Glanville, J., Grimshaw, J.M., Hróbjartsson, A., Lalu, M.M., Li, T., Loder, E.W., Mayo-Wilson, E., Mcdonald, S., Mcguinness, L.A., Stewart, L.A., Thomas, J., Tricco, A.C., Welch, V.A., Whiting, P., Moher, D., 2021. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, n71.

Park, J.N., Rouhani, S., Beletsky, L., Vincent, L., Saloner, B., Sherman, S.G., 2020. Situating the Continuum of Overdose Risk in the Social Determinants of Health: A New Conceptual Framework. Milbank Q 98(3), 700-746.

Park, J.N., Weir, B.W., Allen, S.T., Chaulk, P., Sherman, S.G., 2018. Fentanyl-contaminated drugs and nonfatal overdose among people who inject drugs in Baltimore, MD. Harm Reduct J 15(1), 34.

Pearce, L.A., Min, J.E., Piske, M., Zhou, H., Homayra, F., Slaunwhite, A., Irvine, M., Mcgowan, G., Nosyk, B., 2020. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. BMJ, m772.

Pedersen, J.S., Dong, H., Small, W., Wood, E., Nguyen, P., Kerr, T., Hayashi, K., 2016. Declining trends in the rates of assisted injecting: a prospective cohort study. Harm Reduct J 13, 2.

Peters, P.J., Pontones, P., Hoover, K.W., Patel, M.R., Galang, R.R., Shields, J., Blosser, S.J., Spiller, M.W., Combs, B., Switzer, W.M., Conrad, C., Gentry, J., Khudyakov, Y., Waterhouse, D., Owen, S.M., Chapman, E., Roseberry, J.C., Mccants, V., Weidle, P.J., Broz, D., Samandari, T., Mermin, J., Walthall, J., Brooks, J.T., Duwve, J.M., 2016. HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014–2015. New England Journal of Medicine 375(3), 229-239.

Prangnell, A., Nosova, E., Milloy, M.J., Wood, E., Hayashi, K., 2019. The relationship between parental heavy drinking and non-fatal overdose among people who inject drugs in Vancouver, Canada. Addict Behav 89, 224-228.

Rafful, C., Orozco, R., Rangel, G., Davidson, P., Werb, D., Beletsky, L., Strathdee, S.A., 2018. Increased non-fatal overdose risk associated with involuntary drug treatment in a longitudinal study with people who inject drugs. Addiction 113(6), 1056-1063.

Rafful, C., Wagner, K.D., Werb, D., González-Zúñiga, P.E., Verdugo, S., Rangel, G., Strathdee, S.A., 2015. Prevalence and correlates of neck injection among people who inject drugs in Tijuana, Mexico. Drug Alcohol Rev 34(6), 630-636.

Rigg, K.K., Monnat, S.M., Chavez, M.N., 2018. Opioid-related mortality in rural America: Geographic heterogeneity and intervention strategies. International Journal of Drug Policy 57, 119-129.

Riley, E.D., Evans, J.L., Hahn, J.A., Briceno, A., Davidson, P.J., Lum, P.J., Page, K., 2016. A Longitudinal Study of Multiple Drug Use and Overdose Among Young People Who Inject Drugs. Am J Public Health 106(5), 915-917.

Robinson, W.T., Kazbour, C., Nassau, T., Fisher, K., Sheu, S., Rivera, A.V., Al-Tayyib, A., Glick, S.N., Braunstein, S., Barak, N., Shinefeld, J., Poe, J., Raymond, H.F., Brady, K., 2017. Brief Report: Nonfatal Overdose Events Among Persons Who Inject Drugs: Findings From Seven National HIV Behavioral Surveillance Cities 2009 & 2012. J Acquir Immune Defic Syndr 75 Suppl 3, S341-S345.

Rosenthal, E.S., Silk, R., Mathur, P., Gross, C., Eyasu, R., Nussdorf, L., Hill, K., Brokus, C., D'Amore, A., Sidique, N., Bijole, P., Jones, M., Kier, R., McCullough, D., Sternberg, D., Stafford, K., Sun, J., Masur, H., Kottilil, S., Kattakuzhy, S., 2020. Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs. Clin Infect Dis.

Saloner, B., Mcginty, E.E., Beletsky, L., Bluthenthal, R., Beyrer, C., Botticelli, M., Sherman, S.G., 2018. A Public Health Strategy for the Opioid Crisis. Public Health Reports 133(1\_suppl), 24S-34S.

Selfridge, M., Cunningham, E.B., Milne, R., Drost, A., Barnett, T., Lundgren, K., Guarasci, K., Grebely, J., Fraser, C., 2019. Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada. Int J Drug Policy 72, 106-113. Serota, D.P., Bartholomew, T.S., Tookes, H.E., 2020. Evaluating Differences in Opioid and Stimulant Useassociated Infectious Disease Hospitalizations in Florida, 2016–2017. Clinical Infectious Diseases. Singh, K., Chander, G., Lau, B., Edwards, J.K., Moore, R.D., Lesko, C.R., 2019. Association of History of Injection Drug Use with External Cause-Related Mortality Among Persons Linked to HIV Care in an Urban Clinic, 2001-2015. AIDS Behav 23(12), 3286-3293.

Sun, J., Mehta, S.H., Astemborski, J., Piggott, D.A., Genberg, B.L., Woodson-Adu, T., Benson, E.M., Thomas, D.L., Celentano, D.D., Vlahov, D., Kirk, G.D., 2021. Mortality among persons who inject drugs: A prospective cohort followed over three decades in Baltimore, Maryland, USA. Addiction.

Tobin, K., Clyde, C., Davey-Rothwell, M., Latkin, C., 2018. Awareness and access to naloxone necessary but not sufficient: Examining gaps in the naloxone cascade. Int J Drug Policy 59, 94-97.

Trayner, K.M.A., McAuley, A., Palmateer, N.E., Goldberg, D.J., Shepherd, S.J., Gunson, R.N., Tweed, E.J., Priyadarshi, S., Milosevic, C., Hutchinson, S.J., 2020. Increased risk of HIV and other drug-related harms associated with injecting in public places: national bio-behavioural survey of people who inject drugs. Int J Drug Policy 77, 102663.

Tucker, D., Hayashi, K., Milloy, M.J., Nolan, S., Dong, H., Kerr, T., Wood, E., 2016. Risk factors associated with benzodiazepine use among people who inject drugs in an urban Canadian setting. Addict Behav 52, 103-107.

Tucker, D., Milloy, M.J., Hayashi, K., Nguyen, P., Kerr, T., Wood, E., 2015. Factors associated with illicit methadone injecting in a Canadian setting. Am J Addict 24(6), 532-537.

Uhlmann, S., DeBeck, K., Simo, A., Kerr, T., Montaner, J.S., Wood, E., 2014. Health and social harms associated with crystal methamphetamine use among street-involved youth in a Canadian setting. Am J Addict 23(4), 393-398.

Vallance, K., Pauly, B., Wallace, B., Chow, C., Perkin, K., Martin, G., Zhao, J., Stockwell, T., 2018. Factors associated with public injection and nonfatal overdose among people who inject drugs in street-based settings. Drugs: Education, Prevention and Policy 25(1), 38-46.

Viechtbauer, W., 2010. Conducting Meta-Analyses in R with the metafor Package. Journal of Statistical Software 36(3), 1 - 48.

Wagner, K.D., Armenta, R.F., Roth, A.M., Maxwell, J.C., Cuevas-Mota, J., Garfein, R.S., 2014. Use of synthetic cathinones and cannabimimetics among injection drug users in San Diego, California. Drug and Alcohol Dependence 141, 99-106.

Wagner, K.D., Liu, L., Davidson, P.J., Cuevas-Mota, J., Armenta, R.F., Garfein, R.S., 2015. Association between non-fatal opioid overdose and encounters with healthcare and criminal justice systems: Identifying opportunities for intervention. Drug Alcohol Depend 153, 215-220.

Wakeman, S.E., Larochelle, M.R., Ameli, O., Chaisson, C.E., Mcpheeters, J.T., Crown, W.H., Azocar, F., Sanghavi, D.M., 2020. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Network Open 3(2), e1920622.

Wallace, B., Kennedy, M.C., Kerr, T., Pauly, B., 2019. Factors Associated with Nonfatal Overdose During a Public Health Emergency. Subst Use Misuse 54(1), 39-45.

Warner-Smith, M., Darke, S., Day, C., 2002. Morbidity associated with non-fatal heroin overdose. Addiction 97(8), 963-967.

Weir, M.A., Slater, J., Jandoc, R., Koivu, S., Garg, A.X., Silverman, M., 2019. The risk of infective endocarditis among people who inject drugs: a retrospective, population-based time series analysis. Canadian Medical Association Journal 191(4), E93-E99.

West, B.S., Abramovitz, D.A., Gonzalez-Zuniga, P., Rangel, G., Werb, D., Cepeda, J., Beletsky, L., Strathdee, S.A., 2020. Drugs, discipline and death: Causes and predictors of mortality among people who inject drugs in Tijuana, 2011-2018. Int J Drug Policy 75, 102601.

Winter, R.J., Stoové, M., Degenhardt, L., Hellard, M.E., Spelman, T., Jenkinson, R., McCarthy, D.R., Kinner, S.A., 2015. Incidence and predictors of non-fatal drug overdose after release from prison among people who inject drugs in Queensland, Australia. Drug Alcohol Depend 153, 43-49.

Zibbell, J.E., Asher, A.K., Patel, R.C., Kupronis, B., Iqbal, K., Ward, J.W., Holtzman, D., 2018. Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014. American Journal of Public Health 108(2), 175-181.

# Main Tables and Figures for "Systematic review and meta-analysis to estimate the burden of fatal and non-fatal overdose among people who inject drugs."




Figure 1. PRISMA Flow Chart

Table 1	Non-Fatal	and Fatal	Overdose	Rates	Estimates	Among	PWID	(N=35)	
---------	-----------	-----------	----------	-------	-----------	-------	------	--------	--

Author/Publication YearYearsNPY ContributedNon-Fatal Rate (95% CI)Fatal Rate (95% CI)Berts et al. 2013 [a]AustraliaCross Sectional2011-2011 $6790$ $4707$ $7.90(7.14 = 8.75)$ Horyniak et al. 2013 [b]AustraliaCross Sectional2008-2010 $688$ $344$ $19.77(15.59 = 25.07)$ Versen et al. 2017AustraliaCross Sectional2008-2010 $688$ $344$ $19.77(15.59 = 25.07)$ Kimber et al. 2017AustraliaCohort1999-2010 $215$ $107.52,2055$ $24.19(16.47 = -35.22)$ Mumbiar et al. 2015AustraliaCohort2008-2010 $591$ $292.12$ $27.04(21.69 = -33.72)$ Winter et al. 2015AustraliaCohort2006-2017 $811$ $4928.1$ $0.39(0.25 = 0.60)$ Seffridge et al. 2019CanadaCohort2016-2018 $671$ $2341$ $19.18(17.48 = -21.04)$ Seffridge et al. 2019CanadaCohort2016-2017 $811$ $4928.1$ $0.39(0.25 = 0.60)$ Seffridge et al. 2019CanadaCohort2016-2012 $1019$ $590.5$ $21.98(18.26 = 26.45)$ Vallace et al. 2019CanadaCohort2011-2017 $671$ $335.5$ $20.93(16.09 = -77.8)$ Rafful et al. 2018CanadaCross Sectional2011-2017 $671$ $335.5$ $20.93(15.59 = -25.15)$ Vallace et al. 2019CanadaCohort2011-2017 $671$ $335.5$ $20.93(16.59 = -77.8)$ Rafful et al. 2018MexicoCohort2011-2017				<b>Data Collection</b>						
	<b>Author/Publication Year</b>	Country	Study Design	Years	Ν	<b>PY Contributed</b>	Non-Fatal Rate (95% CI)	Fatal Rate (95% CI)		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Betts et al. 2015	Australia	Cross Sectional	2011-2013	2673	222.75	47.14 (38.93 - 57.07)			
	Horyniak et al. 2013 [a]	Australia	Cross Sectional	2001-2011	6790	4707	7.90 (7.14 - 8.75)			
Kindser et al. 2019AustraliaCohort1999-2010215107.5; 2095 $24.19 (16.47 - 35.52)$ $0.24 (0.10 - 0.57)$ $0.53 (0.30 - 0.93)$ Nambiar et al. 2015AustraliaExperimental2008-2012 $665$ $2277$ $0.53 (0.30 - 0.93)$ ACCTSS DataCanadaCohort2010-2018 $671$ $292.12$ $27.04 (21.69 - 33.72)$ ACCTSS DataCanadaCohort2010-2018 $671$ $4928.1$ $0.39 (0.25 - 0.60)$ Selfridge et al. 2019CanadaCohort $2014-2017$ $132$ $171$ $5.26 (2.74 - 10.12)$ Uhimam et al. 2014CanadaCohort $2016-2018$ $548$ $548$ $1861 (15.33 - 22.60)$ Vallance et al. 2018CanadaCohort $2010-2018$ $980$ $3434.5$ $24.92 (23.31 - 26.65)$ Vallance et al. 2019CanadaCohort $2011-2017$ $671$ $335.5$ $203 (15.95 - 25.15)$ Waltace et al. 2018MexicoCohort $2011-2017$ $671$ $335.5$ $203 (15.95 - 25.16)$ Waltace et al. 2018MexicoCohort $2011-2017$ $671$ $335.5$ $203 (16.30 - 24.07)$ Altar et al. 2018MexicoCohort $2014-2015$ $510$ $19.80 (16.30 - 24.07)$ Altar et al. 2018SwedenCohort $2015-2018$ $3850$ $15.35 (14.16 - 16.64)$ Folde tal. 2018SwedenCohort $2015-2017$ $844$ $407$ $55.53 (48.74 - 63.26)$ Calva et al. 2017United StatesCross Sectional $2015-2018$ $389$ <	Horyniak et al. 2013 [b]	Australia	Cross Sectional	2008-2010	688	344	19.77 (15.59 - 25.07)			
Nambiar et al. 2015AustraliaCohort2008-201266522770.53 $(0.30 - 0.93)$ Winter et al. 2015AustraliaExperimental2008-2010591292.1227.04 $(21.69 - 33.72)$ ACCESS DataCanadaCohort2006-20178114928.10.39 $(0.25 - 0.60)$ Selfridge et al. 2019CanadaCohort2006-20171321715.26 $(2.74 - 10.12)$ Vallance et al. 2014CanadaCohort2008-201554854818.61 $(15.33 - 22.60)$ Vallance et al. 2014CanadaCross Sectional2008-201554854818.61 $(15.33 - 22.60)$ VIDUS DataCanadaCross Sectional201618793.559.80 $(4.609 - 77.83)$ Rafful et al. 2019CanadaCross Sectional201618793.529.80 $(4.609 - 77.83)$ Rafful et al. 2018MexicoCohort2011-201767133.5.520.03 $(1.555 - 25.15)$ 0.46 $(0.33 - 0.64)$ West et al. 2019CanadaCross Sectional2014-201551051019.80 $(16.30 - 24.07)$ 0.32 $(0.26 - 0.40)$ O'Hallorn et al. 2017United KingdomCross Sectional2015-20182850385015.35 $(14.16 - 16.64)$ O'Hallorn et al. 2017United KingdomCross Sectional2015-201829.959.921.37 $(17.97 - 25.41)$ Alt-Tayyb et al. 2017United KingdomCross Sectional2015-201822517.77 $(6.70 - 9.02)$ Calvo et al. 2017United KingdomCross Sectional <td>Iversen et al. 2017</td> <td>Australia</td> <td>Cross Sectional</td> <td>2014</td> <td>1488</td> <td>1488</td> <td>20.77 (18.58 - 23.22)</td> <td></td>	Iversen et al. 2017	Australia	Cross Sectional	2014	1488	1488	20.77 (18.58 - 23.22)			
Winter et al. 2015AustraliaExperimental2008-2010591292.12 $27.04 (21.69 - 33.72)$ ACCESS DataCanadaCohort2006-20178114228.119.18 (17.48 - 21.04)Kennedy et al. 2019CanadaCohort2006-2017132171526 (2.74 - 10.12)Uhlmann et al. 2014CanadaCohort2005-20121019509.521.98 (18.26 - 26.45)Villance et al. 2018CanadaCohort2005-20121019509.521.98 (18.26 - 26.45)Villance et al. 2018CanadaCohort2010-2018980343.4524.92 (2.3.1 - 26.65)Villo ID DataCanadaCohort2011-2017671335.550.89 (4.60 - 77.83)Rafful et al. 2018MexicoCohort2011-2017671335.550.89 (4.60 - 77.83)Wallace et al. 2018SpainCohort2014-201551051019.80 (16.30 - 24.07)Ahman et al. 2018MexicoCohort2014-201551051019.80 (16.30 - 24.07)Ahman et al. 2018SpainCoso Sectional2013-20143850385015.35 (14.16 - 16.64)O'Hallorn et al. 2017United KingdomCross Sectional2013-20143850385015.35 (14.16 - 16.64)Ahrany it al. 2017United StatesCross Sectional2015-201559959921.37 (17.97 - 25.41)Bulthenthal et al. 2017United StatesCross Sectional2014-201522517.77 (6.70 - 9.02)Carls on et al. 2017<	Kimber et al. 2019	Australia	Cohort	1999-2010	215	107.5; 2095	24.19 (16.47 - 35.52)	0.24 (0.10 - 0.57)		
ACCESS DataCanadaCohort2010-2018671234119.18 (17.48 $-$ 21.04)Kennedy et al. 2019CanadaCohort2006-20178114928.10.39 (0.25 $-$ 0.60)Selfridge et al. 2019CanadaCohort2014-20171321715.26 (.74 $-$ 10.12)Uhlmann et al. 2014CanadaCohort2005-20121019509.521.98 (18.26 $-$ 26.45)Vallance et al. 2018CanadaCross Sectional2008-201554854818.61 (15.33 $-$ 22.60)VIDUS DataCanadaCross Sectional201618793.559.89 (46.09 $-$ 77.83)Wallace et al. 2019CanadaCross Sectional201618793.559.89 (46.09 $-$ 77.83)Wallace tal. 2018MexicoCohort2011-2017671335.520.03 (15.95 $-$ 25.15)Vallanc et al. 2018MexicoCohort2014-201551051019.80 (16.30 $-$ 24.07)Ahma et al. 2018SwelenCohort1987-20112019276980.32 (0.26 $-$ 0.40)O'Halloran et al. 2017United KingdomCross Sectional2017-20181437143718.37 (16.28 $-$ 20.73)Al-Taypib et al. 2020United KingdomCross Sectional2014-20152512517.17 (6.70 $-$ 9.02)Carlson et al. 2017United StatesCross Sectional2014-20152522517.77 (6.70 $-$ 9.02)Carlson et al. 2017United StatesCross Sectional2014-2015252112.577.11 (15.12 $-$ 8.85.3)	Nambiar et al. 2015	Australia	Cohort	2008-2012	665	2277		0.53 (0.30 - 0.93)		
Kennedy et al. 2019CanadaCohort2006-20178114928.10.39 (0.25 $-$ 0.60)Selfridge et al. 2019CanadaCohort2014-20171321715.26 (2.74 $-$ 10.12)Ulblmann et al. 2014CanadaCohort2005-20121019509.521.98 (18.26 $-$ 26.45)Vallance et al. 2018CanadaCorss Sectional2008-201554854818.61 (15.33 $-$ 22.60)VIDUS DataCanadaCorss Sectional201618793.559.89 (6.60 $-$ 77.83)Rafful et al. 2018MexicoCohort2011-201767133.5.520.03 (15.95 $-$ 25.15)West et al. 2020MexicoCohort2014-20155105109.80 (16.30 $-$ 24.07)Ahman et al. 2018SpainCross Sectional2014-20155105109.80 (16.30 $-$ 24.07)OHalloran et al. 2017United KingdomCross Sectional2013-20143850385015.35 (14.16 $-$ 16.64)Targure et al. 2020United KingdomCross Sectional2014-201559959921.37 (17.97 $-$ 25.41)OHalloran et al. 2017United KingdomCross Sectional2016-201781440755.35 (48.74 $-$ 63.26)Carlson et al. 2020United StatesCross Sectional2014-2015225117.77 (6.70 $-$ 9.02)Carlson et al. 2017United StatesCross Sectional2014-2015225112.57.111 (57.12 $-$ 88.53)Dedue tal. 2017United StatesCross Sectional2014-2015225112.5<	Winter et al. 2015	Australia	Experimental	2008-2010	591	292.12	27.04 (21.69 - 33.72)			
Selfridge et al. 2019CanadaCohort2014-2017132171 $5.26(2.74-10.12)$ Uhlmann et al. 2014CanadaCohort2005-20121019509.521.98 (18.26-26.45)Vallance et al. 2018CanadaCoss Sectional2008-201554854818.61 (15.33-22.60)VIDUS DataCanadaCoss Sectional2010-20189803434.524.92 (23.31-26.65)Wallace et al. 2019CanadaCross Sectional201618793.559.89 (46.09 -77.83)Arfful et al. 2018MexicoCohort2011-20186587471.260.46 (0.33 - 0.64)Vest et al. 2020MexicoCohort2011-20186587471.260.32 (0.26 - 0.40)O'Halloran et al. 2017United KingdomCross Sectional2013-20143850385015.35 (14.16 - 16.64)Trayner et al. 2020United KingdomCross Sectional2017-201814371437183.77 (16.28 - 20.73)Al-Taryjöt et al. 2017United StatesCross Sectional201559921.37 (17.97 - 25.41)Jutied StatesCross Sectional2015225122517.77 (6.70 - 9.02)Carlson et al. 2017United StatesCross Sectional201781440755.53 (48.74 - 63.26)Carlson et al. 2016United StatesCross Sectional201781440755.53 (49.74 - 63.26)Carlson et al. 2017United StatesCross Sectional2017-20181437143714371497Davis et al.	ACCESS Data	Canada	Cohort	2010-2018	671	2341	19.18 (17.48 - 21.04)			
Uhlmann et al. 2014CanadaCohort2005-20121019509.521.98 (18.26 - 26.45)Vallance et al. 2018CanadaCross Sectional2008-201554854818.61 (15.33 - 22.60)VIDUS DataCanadaCohort2010-20189803434.524.92 (23.31 - 26.65)Wallace et al. 2019CanadaCross Sectional201618793.559.89 (46.09 - 77.83)Raffil et al. 2018MexicoCohort2011-2017671335.520.03 (15.95 - 25.15)West et al. 2020MexicoCohort2011-20186587471.260.46 (0.33 - 0.64)Folk et al. 2018SpainCross Sectional2014-201551051019.80 (16.30 - 24.07)Ahman et al. 2017United KingdomCross Sectional2013-20143850385015.35 (14.16 - 16.64)Trayner et al. 2020United KingdomCross Sectional201559959921.37 (17.97 - 25.41)Bluthenthal et al. 2020United KingdomCross Sectional2016-201781440755.53 (48.74 - 65.26)Calvo et al. 2017United StatesCross Sectional2016-201781440755.53 (48.74 - 65.26)Carlson et al. 2020United StatesCross Sectional201322511.2571.11 (57.12 - 88.53)Cedrabum et al. 2016United StatesCross Sectional201323628332.51 (26.50 - 39.88)Calvo et al. 2017United StatesCross Sectional201621828332.51 (2	Kennedy et al. 2019	Canada	Cohort	2006-2017	811	4928.1		0.39 (0.25 - 0.60)		
Vallance et al. 2018CanadaCross Sectional2008-2015548548 $18.61 (15.33 - 22.60)$ VIDUS DataCanadaCohort2010-20189803434.5 $24.92 (23.31 - 26.65)$ Wallace et al. 2019CanadaCross Sectional201618793.5 $59.89 (46.09 - 77.83)$ Rafful et al. 2018MexicoCohort2011-2017671335.5 $20.03 (15.95 - 25.15)$ West et al. 2020MexicoCohort2011-20186587471.260.46 (0.33 - 0.64)Folch et al. 2018SwedenCross Sectional2014-201551051019.80 (16.30 - 24.07)Ahman et al. 2017United KingdomCross Sectional2013-20143850385015.35 (14.16 - 16.64)Trayner et al. 2020United KingdomCross Sectional2015-20143850385015.35 (14.16 - 16.64)Trayner et al. 2020United KingdomCross Sectional2015-20143850385015.35 (14.76 - 8.62)O'Halloran et al. 2020United KingdomCross Sectional2015-201414371437183.7 (16.28 - 20.73)Al-Tayner et al. 2020United KingdomCross Sectional2016-201781440755.3 (48.74 - 63.26)Calvo et al. 2017United StatesCross Sectional2016-201781440755.3 (48.74 - 63.26)Calvo et al. 2017United StatesCross Sectional2016-201838924.24 (19.97 - 29.86)Calvo et al. 2017United StatesCross Sectional2016283 </td <td>Selfridge et al. 2019</td> <td>Canada</td> <td>Cohort</td> <td>2014-2017</td> <td>132</td> <td>171</td> <td></td> <td>5.26 (2.74 - 10.12)</td>	Selfridge et al. 2019	Canada	Cohort	2014-2017	132	171		5.26 (2.74 - 10.12)		
VIDUS DataCanadaCohort2010-20189803434.5 $24.92$ ( $23.31 - 26.65$ )Wallace et al. 2019CanadaCross Sectional201618793.5 $59.89$ ( $46.09 - 77.83$ )Rafful et al. 2018MexicoCohort2011-2017 $671$ $335.5$ $20.03$ ( $15.95 - 25.15$ )West et al. 2020MexicoCohort2011-2018 $658$ $7471.26$ $0.46$ ( $0.33 - 0.64$ )Folch et al. 2018SpainCross Sectional2014-2015 $510$ $510$ $19.80$ ( $16.30 - 24.07$ )Ahman et al. 2018SwedenCohort1987-20112019 $27698$ $0.32$ ( $0.26 - 0.40$ )O'Halloran et al. 2017United KingdomCross Sectional2013-2014 $3850$ $3850$ $15.35$ ( $14.16 - 16.64$ )Trayner et al. 2017United KingdomCross Sectional2017-2018 $1437$ $1437$ $18.37$ ( $16.28 - 20.73$ )Al-Tayyib et al. 2017United StatesCross Sectional2014-2015 $251$ $2251$ $7.77$ ( $6.70 - 9.02$ )Calvo et al. 2017United StatesCross Sectional2014-2015 $2251$ $2251$ $7.77$ ( $6.70 - 9.02$ )Carlson et al. 2017United StatesCross Sectional2016 $283$ $283$ $23.21(2.650 - 39.88)$ Davis et al. 2017United StatesCross Sectional2016 $283$ $283$ $32.51$ ( $26.50 - 39.88$ )Latkin et al. 2019United StatesCross Sectional2016 $283$ $283$ $32.51$ ( $26.50 - 39.88$ )Latkin et al. 2019Un	Uhlmann et al. 2014	Canada	Cohort	2005-2012	1019	509.5	21.98 (18.26 - 26.45)			
Wallace et al. 2019CanadaCross Sectional201618793.559.89 (46.09 $-$ 77.8)Raffil et al. 2018MexicoCohort2011-2017671335.520.03 (15.95 $-$ 25.15)West et al. 2020MexicoCohort2011-20186587471.260.46 (0.33 $-$ 0.64)Folch et al. 2018SpainCross Sectional2014-201551051019.80 (16.30 $-$ 24.07)Åhman et al. 2018SwedenCohort1987-20112019276980.32 (0.26 $-$ 0.40)O'Halloran et al. 2017United KingdomCross Sectional2013-20143850385015.35 (14.16 $-$ 16.64)Trayner et al. 2020United KingdomCross Sectional2017-20181437143718.37 (16.28 $-$ 20.73)Al-Tayyib et al. 2017United StatesCross Sectional2016-201781440755.53 (48.74 $-$ 63.26)Calvo et al. 2017United StatesCross Sectional2014-201522517.77 (6.70 $-$ 9.02)Calvo et al. 2017United StatesCross Sectional20133893892424 (19.97 $-$ 29.86)Cadvo et al. 2016United StatesCross Sectional201628328332.51 (26.50 $-$ 39.88)Latkin et al. 2019United StatesCross Sectional201628328332.51 (26.50 $-$ 39.88)Latkin et al. 2019United StatesCross Sectional201628328332.51 (26.50 $-$ 39.88)Latkin et al. 2019United StatesCross Sectional2016283 <td>Vallance et al. 2018</td> <td>Canada</td> <td>Cross Sectional</td> <td>2008-2015</td> <td>548</td> <td>548</td> <td>18.61 (15.33 - 22.60)</td> <td></td>	Vallance et al. 2018	Canada	Cross Sectional	2008-2015	548	548	18.61 (15.33 - 22.60)			
Rafful et al. 2018MexicoCohort2011-2017671335.520.03 ( $15.95-25.15$ )West et al. 2020MexicoCohort2011-20186587471.260.46 ( $0.33-0.64$ )Folch et al. 2018SpainCross Sectional2014-201551051019.80 ( $16.30-24.07$ )Åhman et al. 2018SwedenCohort1987-20112019276980.32 ( $0.26-0.40$ )O'Halloran et al. 2017United KingdomCross Sectional2017-2018143718.37 ( $16.28-20.73$ )Al-Tayyib et al. 2017United KingdomCross Sectional201559959921.37 ( $17.97-25.41$ )Bluthenthal et al. 2020United StatesCross Sectional2014-2015225127.67.0-9.02)Calvo et al. 2017United StatesCross Sectional2014-201522517.11 ( $57.12-88.53$ )Calvo et al. 2017United StatesCross Sectional2014-201522517.11 ( $57.12-88.53$ )Carlson et al. 2020United StatesCross Sectional2017-2018225112.57.11 ( $57.12-88.53$ )Cedarbaum et al. 2016United StatesCohort1996-2011200753391.09 ( $0.84-1.41$ )Hunter et al. 2019United StatesCross Sectional2016-201831631631.631.6Davis et al. 2017United StatesCross Sectional201628328332.51 ( $26.50-39.88$ )Latvin et al. 2019United StatesCross Sectional2016201831631.631.6	VIDUS Data	Canada	Cohort	2010-2018	980	3434.5	24.92 (23.31 - 26.65)			
West et al. 2020MexicoCohort2011-20186587471.260.46 (0.33 - 0.64)Folch et al. 2018SpainCross Sectional2014-201551051019.80 (16.30 - 24.07)0.32 (0.26 - 0.40)Åhman et al. 2018SwedenCohort1987-20112019276980.32 (0.26 - 0.40)O'Halloran et al. 2017United KingdomCross Sectional2013-20143850385015.35 (14.16 - 16.64)Trayner et al. 2020United KingdomCross Sectional2017-2018143718.37 (16.28 - 20.73)Al-Tayyib et al. 2017United StatesCross Sectional2016-201781440755.53 (48.74 - 63.26)Calvo et al. 2017United StatesCross Sectional2014-201522517.17 (6.70 - 9.02)Carlson et al. 2020United StatesCross Sectional201338938924.42 (19.97 - 29.86)Davis et al. 2017United StatesCross Sectional201628328332.51 (26.50 - 39.88)Cedarbaum et al. 2018United StatesCross Sectional2016-201831631635.13 (29.16 - 42.31)Hunter et al. 2018United StatesCross Sectional2016-2018316316.4335.13 (29.16 - 42.31)Or Courke et al. 2019United StatesCross Sectional201628328332.51 (26.50 - 39.88)Davis et al. 2019United StatesCross Sectional2018373186.587.40 (74.96 - 101.90)I tatkin et al. 2020United StatesCross Sectional	Wallace et al. 2019	Canada	Cross Sectional	2016	187	93.5	59.89 (46.09 - 77.83)			
Folch et al. 2018SpainCross Sectional2014-201551051019.80 ( $16.30 - 24.07$ )0.32 ( $0.26 - 0.40$ )Åhman et al. 2018SwedenCohort1987-20112019276980.32 ( $0.26 - 0.40$ )O'Halloran et al. 2017United KingdomCross Sectional2013-20143850385015.35 ( $14.16 - 16.64$ )Trayner et al. 2020United KingdomCross Sectional2017-20181437143718.37 ( $16.28 - 20.73$ )Al-Tayyib et al. 2017United StatesCross Sectional201559959921.37 ( $1.797 - 25.41$ )Bluthenthal et al. 2020United StatesCross Sectional2016-201781440755.53 ( $48.74 - 63.26$ )Calvo et al. 2017United StatesCross Sectional2017-201822517.77 ( $6.70 - 9.02$ )Carlson et al. 2020United StatesCross Sectional2017-2018225112.571.11 ( $57.12 - 88.53$ )Cedarbaum et al. 2016United StatesCross Sectional201628328332.51 ( $26.50 - 39.88$ )Davis et al. 2017United StatesCross Sectional201628328332.51 ( $26.50 - 39.88$ )Hunter et al. 2018United StatesCross Sectional201831631635.13 ( $29.16 - 42.31$ )O'Neurk et al. 2019United StatesCross Sectional201837.3186.587.40 ( $74.96 - 101.90$ )I hunter et al. 2020United StatesCross Sectional201837.3186.587.40 ( $74.96 - 101.90$ )Ride et	Rafful et al. 2018	Mexico	Cohort	2011-2017	671	335.5	20.03 (15.95 - 25.15)			
Åhman et al. 2018ŚwedenCohort1987-2011201927698 $0.32 (0.26 - 0.40)$ O'Halloran et al. 2017United KingdomCross Sectional2013-20143850385015.35 (14.16 - 16.64)Trayner et al. 2020United KingdomCross Sectional2017-20181437143718.37 (16.28 - 20.73)Al-Tayyib et al. 2017United StatesCross Sectional201559959921.37 (17.97 - 25.41)Bluthenthal et al. 2020United StatesCross Sectional2016-201781440755.53 (48.74 - 63.26)Calvo et al. 2017United StatesCross Sectional2017-201822517.77 (6.70 - 9.02)Carlson et al. 2020United StatesCross Sectional2017-2018225112.571.11 (57.12 - 88.53)Cedarbaum et al. 2016United StatesCross Sectional2016-2011200753391.09 (0.84 - 1.41)Hunter et al. 2017United StatesCross Sectional2016-201831631635.13 (29.16 - 42.31)Hunter et al. 2018United StatesCross Sectional2016-201831631635.13 (29.16 - 42.31)Hunter et al. 2019United StatesCross Sectional2018373186.587.40 (74.96 - 101.90)O'Rourke et al. 2019United StatesCross Sectional2018373186.587.40 (74.96 - 101.90)O'Rourke et al. 2016United StatesCohort202.2014173139.619.34 (13.26 - 28.20)O'Rourke et al. 2016United States <td>West et al. 2020</td> <td>Mexico</td> <td>Cohort</td> <td>2011-2018</td> <td>658</td> <td>7471.26</td> <td></td> <td>0.46 (0.33 - 0.64)</td>	West et al. 2020	Mexico	Cohort	2011-2018	658	7471.26		0.46 (0.33 - 0.64)		
O'Halloran et al. 2017United KingdomCross Sectional2013-201438503850 $15.35 (14.16 - 16.64)$ Trayner et al. 2020United KingdomCross Sectional2017-201814371437 $18.37 (16.28 - 20.73)$ Al-Tayyib et al. 2017United StatesCross Sectional2015599599 $21.37 (17.97 - 25.41)$ Bluthenthal et al. 2020United StatesCross Sectional2016-2017814407 $55.53 (48.74 - 63.26)$ Calvo et al. 2017United StatesCross Sectional2014-201522512251 $7.77 (6.70 - 9.02)$ Carlson et al. 2020United StatesCross Sectional2017-2018225112.5 $71.11 (57.12 - 88.53)$ Cedarbaum et al. 2016United StatesCross Sectional201628328332.51 (26.50 - 39.88)Davis et al. 2017United StatesCross Sectional2016-201831631635.13 (29.16 - 42.31)Hunter et al. 2018United StatesCross Sectional2016-201831631635.13 (29.16 - 42.31)Oh et al. 2020United StatesCross Sectional2018373186.587.40 (74.96 - 101.90)Okurke et al. 2019United StatesCross Sectional2018373186.587.40 (74.96 - 101.90)Riley et al. 2017United StatesCross Sectional2012-2014173139.619.34 (13.26 - 28.20)Orkourke et al. 2017United StatesCross Sectional2009-20123457345713.28 (12.12 - 14.55)Robins	Folch et al. 2018	Spain	Cross Sectional	2014-2015	510	510	19.80 (16.30 - 24.07)			
Trayner et al. 2020United KingdomCross Sectional2017-20181437143718.37 (16.28 - 20.73)Al-Tayyib et al. 2017United StatesCross Sectional201559959921.37 (17.97 - 25.41)Bluthenthal et al. 2020United StatesCross Sectional2016-201781440755.53 (48.74 - 63.26)Calvo et al. 2017United StatesCross Sectional2014-2015225122517.77 (6.70 - 9.02)Carlson et al. 2020United StatesCross Sectional2017-2018225112.571.11 (57.12 - 88.53)Cedarbaum et al. 2016United StatesCross Sectional201338938924.42 (19.97 - 29.86)Davis et al. 2017United StatesCross Sectional2016-2011200753391.09 (0.84 - 1.41)Hunter et al. 2018United StatesCross Sectional2016-201831631635.13 (29.16 - 42.31)Hunter et al. 2019United StatesCross Sectional2018373186.587.40 (74.96 - 101.90)Riley et al. 2016United StatesCross Sectional2018373139.619.34 (13.26 - 28.20)Riley et al. 2017United StatesCross Sectional2008373136.587.40 (74.96 - 101.90)Riley et al. 2019United StatesCross Sectional2018373139.619.34 (13.26 - 28.20)Riley et al. 2019United StatesCross Sectional2009-20123457345713.28 (12.12 - 14.55)Riley et al. 2017United St	Åhman et al. 2018	Sweden	Cohort	1987-2011	2019	27698		0.32 (0.26 - 0.40)		
Al-Tayyib et al. 2017United StatesCross Sectional2015599599 $21.37 (17.97 - 25.41)$ Bluthenthal et al. 2020United StatesCross Sectional2016-2017814407 $55.53 (48.74 - 63.26)$ Calvo et al. 2017United StatesCross Sectional2014-201522512251 $7.77 (6.70 - 9.02)$ Carlson et al. 2020United StatesCross Sectional2017-2018225112.5 $71.11 (57.12 - 88.53)$ Cedarbaum et al. 2016United StatesCross Sectional201338938924.42 (19.97 - 29.86)Davis et al. 2017United StatesCross Sectional2016283283 $32.51 (26.50 - 39.88)$ Latkin et al. 2018United StatesCross Sectional2016-2018316 $316$ $35.13 (29.16 - 42.31)$ Oh et al. 2020United StatesCross Sectional2018373186.5 $87.40 (74.96 - 101.90)$ Riley et al. 2019United StatesCross Sectional2018373186.5 $87.40 (74.96 - 101.90)$ Riley et al. 2017United StatesCross Sectional2012-2014173139.619.34 (13.26 - 28.20)Robinson et al. 2017United StatesCross Sectional2009-20123457345713.28 (12.12 - 14.55)Rosenthal et al. 2020United StatesCross Sectional2009-20123457345713.28 (14.10 - 43.72)Singh et al. 2019United StatesCohort2012-2014173139.619.34 (13.26 - 28.20)Robinson et al. 2017	O'Halloran et al. 2017	United Kingdom	Cross Sectional	2013-2014	3850	3850	15.35 (14.16 - 16.64)			
Bluthenthal et al. 2020United StatesCross Sectional2016-2017 $814$ 407 $55.53$ ( $48.74 - 63.26$ )Calvo et al. 2017United StatesCross Sectional2014-20152251 $2251$ $7.77$ ( $6.70 - 9.02$ )Carlson et al. 2020United StatesCross Sectional2017-2018225 $112.5$ $71.11$ ( $57.12 - 88.53$ )Cedarbaum et al. 2016United StatesCross Sectional2013389389 $24.42$ ( $19.97 - 29.86$ )Davis et al. 2017United StatesCohort1996-20112007 $5339$ $1.09$ ( $0.84 - 1.41$ )Hunter et al. 2018United StatesCross Sectional2016283283 $32.51$ ( $26.50 - 39.88$ )Latkin et al. 2019United StatesCross Sectional2016-2018316 $316$ $35.13$ ( $29.16 - 42.31$ )O'Rourke et al. 2019United StatesCross Sectional2018 $458$ $458$ $50.87$ ( $44.74 - 57.84$ )O'Rourke et al. 2019United StatesCross Sectional2018 $373$ $186.5$ $87.40$ ( $74.96 - 101.90$ )Riley et al. 2016United StatesCohort2012-2014 $173$ $139.6$ $19.34$ ( $13.26 - 28.20$ )Robinson et al. 2017United StatesCross Sectional2009-2012 $3457$ $3457$ $13.28$ ( $12.12 - 14.55$ )Rosenthal et al. 2020United StatesExperimental2017-2018100 $48.33$ $24.83$ ( $14.10 - 43.72$ )Singh et al. 2019United StatesCohort2001-20151665 $13503$ $0.47$ ( $0.3$	Trayner et al. 2020	United Kingdom	Cross Sectional	2017-2018	1437	1437	18.37 (16.28 - 20.73)			
Calvo et al. 2017United StatesCross Sectional2014–201522512251 $7.77 (6.70 - 9.02)$ Carlson et al. 2020United StatesCross Sectional2017-2018225112.5 $71.11 (57.12 - 88.53)$ Cedarbaum et al. 2016United StatesCross Sectional201338938924.42 (19.97 - 29.86)Davis et al. 2017United StatesCohort1996-2011200753391.09 (0.84 - 1.41)Hunter et al. 2018United StatesCross Sectional201628328332.51 (26.50 - 39.88)Latkin et al. 2019United StatesCross Sectional2016-201831631635.13 (29.16 - 42.31)Oh et al. 2020United StatesCross Sectional201845845850.87 (44.74 - 57.84)O'Rourke et al. 2019United StatesCross Sectional2012-2014173139.619.34 (13.26 - 28.20)Riley et al. 2016United StatesCross Sectional2009-20123457345713.28 (12.12 - 14.55)Robinson et al. 2017United StatesCross Sectional2017-201810048.3324.83 (14.10 - 43.72)Singh et al. 2019United StatesCohort201-20151665135030.47 (0.36 - 0.60)	Al-Tayyib et al. 2017	United States	Cross Sectional	2015	599	599	21.37 (17.97 - 25.41)			
Carlson et al. 2020United StatesCross Sectional2017-2018225112.5 $71.11$ ( $57.12 - 88.53$ )Cedarbaum et al. 2016United StatesCross Sectional201338938924.42 ( $19.97 - 29.86$ )Davis et al. 2017United StatesCohort1996-2011200753391.09 ( $0.84 - 1.41$ )Hunter et al. 2018United StatesCross Sectional201628328332.51 ( $26.50 - 39.88$ )Latkin et al. 2019United StatesCross Sectional2016-201831631635.13 ( $29.16 - 42.31$ )Oh et al. 2020United StatesCross Sectional201845845850.87 ( $44.74 - 57.84$ )O'Rourke et al. 2019United StatesCross Sectional2012-2014173139.619.34 ( $13.26 - 28.20$ )Riley et al. 2017United StatesCross Sectional2009-20123457345713.28 ( $12.12 - 14.55$ )Rosenthal et al. 2020United StatesExperimental2017-201810048.3324.83 ( $14.10 - 43.72$ )Singh et al. 2019United StatesCohort2001-20151665135030.47 ( $0.36 - 0.60$ )	Bluthenthal et al. 2020	United States	Cross Sectional	2016-2017	814	407	55.53 (48.74 - 63.26)			
Cedarbaum et al. 2016United StatesCross Sectional2013389389 $24.42 (19.97 - 29.86)$ Davis et al. 2017United StatesCohort1996-201120075339 $1.09 (0.84 - 1.41)$ Hunter et al. 2018United StatesCross Sectional2016283283 $32.51 (26.50 - 39.88)$ Latkin et al. 2019United StatesCross Sectional2016-2018316 $316$ $35.13 (29.16 - 42.31)$ Oh et al. 2020United StatesCross Sectional2018 $458$ $458$ $50.87 (44.74 - 57.84)$ O'Rourke et al. 2019United StatesCross Sectional2012-2014173139.619.34 (13.26 - 28.20)Riley et al. 2016United StatesCross Sectional2009-20123457345713.28 (12.12 - 14.55)Rosenthal et al. 2020United StatesExperimental2017-2018100 $48.33$ $24.83 (14.10 - 43.72)$ Singh et al. 2019United StatesCohort2001-2015166513503 $0.47 (0.36 - 0.60)$	Calvo et al. 2017	United States	Cross Sectional	2014-2015	2251	2251	7.77 (6.70 - 9.02)			
Davis et al. 2017United StatesCohort1996-201120075339 $1.09 (0.84 - 1.41)$ Hunter et al. 2018United StatesCross Sectional2016283283 $32.51 (26.50 - 39.88)$ Latkin et al. 2019United StatesCross Sectional2016-2018316 $316$ $35.13 (29.16 - 42.31)$ Oh et al. 2020United StatesCross Sectional2018 $458$ $50.87 (44.74 - 57.84)$ O'Rourke et al. 2019United StatesCross Sectional2012 $373$ $186.5$ $87.40 (74.96 - 101.90)$ Riley et al. 2016United StatesCohort2012-2014173 $139.6$ $19.34 (13.26 - 28.20)$ Robinson et al. 2017United StatesCross Sectional2009-2012 $3457$ $3457$ $13.28 (12.12 - 14.55)$ Rosenthal et al. 2020United StatesExperimental2017-2018 $100$ $48.33$ $24.83 (14.10 - 43.72)$ Singh et al. 2019United StatesCohort2001-2015 $1665$ $13503$ $0.47 (0.36 - 0.60)$	Carlson et al. 2020	United States	Cross Sectional	2017-2018	225	112.5	71.11 (57.12 - 88.53)			
Hunter et al. 2018United StatesCross Sectional2016283283 $32.51 (26.50 - 39.88)$ Latkin et al. 2019United StatesCross Sectional2016-2018316316 $35.13 (29.16 - 42.31)$ Oh et al. 2020United StatesCross Sectional2018458 $50.87 (44.74 - 57.84)$ O'Rourke et al. 2019United StatesCross Sectional2018373186.5 $87.40 (74.96 - 101.90)$ Riley et al. 2016United StatesCohort2012-2014173139.6 $19.34 (13.26 - 28.20)$ Robinson et al. 2017United StatesCross Sectional2009-201234573457 $13.28 (12.12 - 14.55)$ Rosenthal et al. 2020United StatesExperimental2017-2018100 $48.33$ $24.83 (14.10 - 43.72)$ Singh et al. 2019United StatesCohort2001-2015166513503 $0.47 (0.36 - 0.60)$	Cedarbaum et al. 2016	United States	Cross Sectional	2013	389	389	24.42 (19.97 - 29.86)			
Latkin et al. 2019United StatesCross Sectional2016-2018316316 $35.13$ (29.16 - 42.31)Oh et al. 2020United StatesCross Sectional2018458458 $50.87$ (44.74 - 57.84)O'Rourke et al. 2019United StatesCross Sectional2018373186.5 $87.40$ (74.96 - 101.90)Riley et al. 2016United StatesCohort2012-2014173139.6 $19.34$ (13.26 - 28.20)Robinson et al. 2017United StatesCross Sectional2009-201234573457 $13.28$ (12.12 - 14.55)Rosenthal et al. 2020United StatesExperimental2017-2018100 $48.33$ $24.83$ (14.10 - 43.72)Singh et al. 2019United StatesCohort2001-2015166513503 $0.47$ (0.36 - 0.60)	Davis et al. 2017	United States	Cohort	1996-2011	2007	5339		1.09 (0.84 - 1.41)		
Oh et al. 2020       United States       Cross Sectional       2018       458       458       50.87 (44.74 - 57.84)         O'Rourke et al. 2019       United States       Cross Sectional       2018       373       186.5       87.40 (74.96 - 101.90)         Riley et al. 2016       United States       Cohort       2012-2014       173       139.6       19.34 (13.26 - 28.20)         Robinson et al. 2017       United States       Cross Sectional       2009-2012       3457       3457       13.28 (12.12 - 14.55)         Rosenthal et al. 2020       United States       Experimental       2017-2018       100       48.33       24.83 (14.10 - 43.72)         Singh et al. 2019       United States       Cohort       2001-2015       1665       13503       0.47 (0.36 - 0.60)	Hunter et al. 2018	United States	Cross Sectional	2016	283	283	32.51 (26.50 - 39.88)			
O'Rourke et al. 2019       United States       Cross Sectional       2018       373       186.5       87.40 (74.96 - 101.90)         Riley et al. 2016       United States       Cohort       2012-2014       173       139.6       19.34 (13.26 - 28.20)         Robinson et al. 2017       United States       Cross Sectional       2009-2012       3457       3457       13.28 (12.12 - 14.55)         Rosenthal et al. 2020       United States       Experimental       2017-2018       100       48.33       24.83 (14.10 - 43.72)         Singh et al. 2019       United States       Cohort       2001-2015       1665       13503       0.47 (0.36 - 0.60)	Latkin et al. 2019	United States	Cross Sectional	2016-2018	316	316	35.13 (29.16 - 42.31)			
Riley et al. 2016       United States       Cohort       2012-2014       173       139.6       19.34 (13.26 - 28.20)         Robinson et al. 2017       United States       Cross Sectional       2009-2012       3457       3457       13.28 (12.12 - 14.55)         Rosenthal et al. 2020       United States       Experimental       2017-2018       100       48.33       24.83 (14.10 - 43.72)         Singh et al. 2019       United States       Cohort       2001-2015       1665       13503       0.47 (0.36 - 0.60)	Oh et al. 2020	United States	Cross Sectional	2018	458	458	50.87 (44.74 - 57.84)			
Robinson et al. 2017         United States         Cross Sectional         2009-2012         3457         3457         13.28 (12.12 - 14.55)           Rosenthal et al. 2020         United States         Experimental         2017-2018         100         48.33         24.83 (14.10 - 43.72)           Singh et al. 2019         United States         Cohort         2001-2015         1665         13503         0.47 (0.36 - 0.60)	O'Rourke et al. 2019	United States	Cross Sectional	2018	373	186.5	87.40 (74.96 — 101.90)			
Rosenthal et al. 2020         United States         Experimental         2017-2018         100         48.33         24.83 (14.10 - 43.72)           Singh et al. 2019         United States         Cohort         2001-2015         1665         13503         0.47 (0.36 - 0.60)	Riley et al. 2016	United States	Cohort	2012-2014	173	139.6	19.34 (13.26 - 28.20)			
Singh et al. 2019         United States         Cohort         2001-2015         1665         13503         0.47 (0.36 - 0.60)	Robinson et al. 2017	United States	Cross Sectional	2009-2012	3457	3457	13.28 (12.12 - 14.55)			
	Rosenthal et al. 2020	United States	Experimental	2017-2018	100	48.33	24.83 (14.10 - 43.72)			
Wagner et al. 2015 United States Cross Sectional 2012-2014 573 286.5 15.71 (11.73 - 21.04)	Singh et al. 2019	United States	Cohort	2001-2015	1665	13503		0.47 (0.36 - 0.60)		
	Wagner et al. 2015	United States	Cross Sectional	2012-2014	573	286.5	15.71 (11.73 - 21.04)			

Person-Years (PY)

Confidence Interval (CI)

\* Non-fatal overdose reported at baseline, fatal overdose measured over follow-up period. Person-years computed from survey look-back for non-fatal but not fatal overdose.

\*\* Excluding unconfirmed deaths

\*\*\* Rates per 100 PY

	n	Rate (95% CI)*	$\tau^2$	I <sup>2</sup>	Q (p-value)
OECD					× <b>•</b>
Non-Fatal	28	24.74 (19.86—30.83)	0.34	98.5%	1750.91 (p<0.0001)
Fatal	8	0.61 (0.32-1.16)	0.80	93.4%	106.80 (p<0.0001)
North America					
Non-Fatal	18	27.79 (20.68—37.35)	0.40	98.5%	1145.45 (p<0.0001)
Australia					
Non-Fatal	6	21.44 (13.32—34.49)	0.34	98.6%	357.90 (p<0.0001)
Canada					
Non-Fatal	5	25.71 (17.07—38.71)	0.21	94.8%	76.30 (p<0.0001)
<b>United States</b>					
Non-Fatal	13	28.59 (19.46-42.02)	0.49	98.9%	1048.51 (p<0.0001)

 Table 2. Non-Fatal and Fatal Overdose Rate Estimates (1987-2018)

\*Estimated from random effects, restricted maximum likelihood models; per 100 PY n: represents the number of studies contributing data




Figure 2. Random-Effects Meta-Analysis of Non-Fatal Overdose Rates Per 100 PY




Figure 3. Random-Effects Meta-Analysis of Fatal Overdose Rates Per 100 PY

# Supplemental Materials For "Systematic review and meta-analysis to estimate the burden of fatal and non-fatal overdose among people who inject drugs."

CONTENTS 1
Appendix 1: Search Strings
Appendix 2: Extended Summary Table 3
Appendix 3: Quality Assessment
3.1: Quality Assessment Summary
3.2: Non-Fatal Overdose Quality Assessment
3.3: Fatal Overdose Quality Assessment
3.4: Quality Assessment Scores7
Appendix 4: North American Forest Plots
4.1: Non-Fatal Overdose Forest Plot
Appendix 5: Country Specific Forrest Plots9
5.1: Australia
5.2: Canada10
5.3: United States 11
Appendix 6: Summary Table of Non-Analyzed Data12

### Appendix 1. Search Strings


Search String	Number of Results
PubMed	
overdose PWID	165
overdose IDU	46
fatal* PWID	53
fatal* IDU	23
mortal* PWID	164
mortal* IDU	177
overdose inject* AND drug	1134
(((overdose or fatal* or mortal*) AND (inject* or PWID or IDU)) AND (drug* or narcotic)) AND	
(NOT rat or mouse or mice))	2530
(((((((overdose or fatal or mortal) AND (inject or PWID or IDU)) AND (drug or narcotic))))) AND	
(("2010"[Date - Publication] : "3000"[Date - Publication]))) NOT (rat)) NOT (mouse)) NOT (mice))	1.500
NOT (dog)) NOT (horse)	1523
Embase	
overdose PWID	204
overdose IDU	98
fatal* PWID	56
fatal* IDU	40
mortal* PWID	258
mortal* IDU	310
overdose inject* AND drug	6262
((('drug overdose'/exp OR 'drug overdose' OR fatal* OR mortal*:af) AND inject* OR pwid OR 'idu'/exp OR idu) AND drug* OR narcotic) NOT ('rat'/exp OR rat) NOT ('mouse'/exp OR mouse)	
NOT ('mice'/exp OR mice) NOT ('dog'/exp OR dog) NOT ('horse'/exp OR horse) NOT ('animal'/exp	
OR animal) AND [1-1-2010]/sd NOT [29-8-2020]/sd	1631
Psychinfo	1001
overdose PWID	35
overdose IDU	14
fatal* PWID	8
fatal* IDU	2
mortal* PWID	15
mortal* IDU	17
overdose inject* AND drug	163
( overdose or poisoning or toxicity ) AND ( fatal or injury ) AND ( mortality or mortality rate or	4164
death or death rate ) AND inject* OR ( pwid or idu or injection drug users or injection drug addicts or	
people who inject drugs ) AND drug use OR narcotics NOT ( case report or case study or clinical	
case ) NOT rats NOT ( mouse or mice )	

Author/Publication Year	Country	<b>Recruitment Period</b>	End of Survey Follow-Up	<b>PY Contributed</b>	<b>Non-Fatal Events</b>	Fatal Events		
Betts et al. 2015	Australia	2011-2013	2013	222.75	105			
Horyniak et al. 2013 [a]	Australia	2001-2011	2011	4707	372			
Horyniak et al. 2013 [b]	Australia	2008-2010	2010	344	68			
Iversen et al. 2017	Australia	2014	2014	1488	309			
Kimber et al. 2019	Australia	1999-2002	2010	107.5; 2095	26	5		
Nambiar et al. 2015	Australia	2008-2010	2012	2277		12		
Winter et al. 2015	Australia	2008-2010	2011	292.12	79			
ACCESS Data	Canada	2006-2014	2018	2341	449			
Kennedy et al. 2019	Canada	2006-2016	2017	4928.1		19		
Selfridge et al. 2019	Canada	2014-2017	2017	171		9		
Uhlmann et al. 2014	Canada	2005-2012	2012	509.5	112			
Vallance et al. 2018	Canada	2008-2015	2015	548	102			
VIDUS Data	Canada	2010-2018?	2018	3434.5		856		
Wallace et al. 2019	Canada	2016	2016	93.5	56			
Rafful et al. 2018	Mexico	2011-2015	2017	335.5	64			
West et al. 2020	Mexico	2011-2013	2018	7471.26		34		
Folch et al. 2018	Spain	2014-2015	2015	510	101			
Åhman et al. 2018	Sweden	1987-2011	2011	27698		89		
O'Halloran et al. 2017	United Kingdom	2013-2014	2014	3850	591			
Trayner et al. 2020	United Kingdom	2017-2018	2018	1437	264			
Al-Tayyib et al. 2017 [a]	United States	2015	2015	599	128			
Bluthenthal et al. 2020	United States	2016-2017	2017	407	226			
Calvo et al. 2017	United States	2014-2015	2015	2251	175			
Carlson et al. 2020	United States	2017-2018	2018	112.5	80			
Cedarbaum et al. 2016	United States	2013	2013	389	95			
Davis et al. 2017	United States	1996-2011	2011	5339		58		
Hunter et al. 2018	United States	2016	2016	283	92			
Latkin et al. 2019	United States	2016-2018	2018	316	111			
Oh et al. 2020	United States	2018	2018	458	233			
O'Rourke et al. 2019	United States	2018	2018	186.5	163			
Riley et al. 2016	United States	2012-2014	2014	139.6	27			
Robinson et al. 2017	United States	2009-2012	2012	3457	459			
Rosenthal et al. 2020	United States	2017-2018	2018	48.33	12			
Singh et al. 2019	United States	2001-2015	2015	13503		63		
Wagner et al. 2015	United States	2012-2014	2014	286.5	45			


## Appendix 2. Extended Summary Table

Person-Years (PY)


Confidence Interval (CI)



Appendix 3.1. Quality Assessment Summary (N=35)



Appendix 3.2. Non-Fatal Overdose Quality Assessment (N=28)



Appendix 3.3. Fatal Overdose Quality Assessment (N=8)

### Table 3.4. Quality Assessment Scores (N=35)

Author/Dublication Voor	Contributed Non-Fatal	Contributed Fatal Estimate	Defined Overdose for Participants	Population- Based Recruitment	Number of PY of Follow-Up Benerted
Author/Publication Year Betts et al. 2015	Estimate	ratai Estimate	Participants	Kecruitment	Reported
Horyniak et al. 2013 [a]					
Horyniak et al. 2013 [b]					
Iversen et al. 2017					
ACCESS Data					
Winter et al. 2015					
Uhlmann et al. 2014					
Vallance et al. 2018					
VIDUS Data					
Wallace et al. 2019	•			•	•
Rafful et al. 2018					
Folch et al. 2018					
O'Halloran et al. 2017					
Trayner et al. 2020			•		
Al-Tayyib et al. 2017	•				
Bluthenthal et al. 2020	•			•	
Calvo et al. 2017					
Carlson et al. 2020					
Cedarbaum et al. 2016					
Hunter et al. 2018					
Latkin et al. 2019					
Oh et al. 2020					
O'Rourke et al. 2019					
Riley et al. 2016					
Robinson et al. 2017					
Rosenthal et al. 2020					
Wagner et al. 2015					
Kimber et al. 2019					
Nambiar et al. 2015					
Kennedy et al. 2019					
Selfridge et al. 2019					
West et al. 2020					
Åhman et al. 2018					
Davis et al. 2017					
Singh et al. 2019					

Person-Years (PY)

Appendix 4. North American Forest Plots

Author & Median Data Collection Date			ts per ′ on−yea		E	Events	95%-C	l Weight
Uhlmann 2008						21.98	[18.27; 26.45	5.6%
Vallance 2012	-					18.61	[15.33; 22.60	5.6%
VIDUS 2014	+					24.92	[23.31; 26.65	5.7%
ACCESS 2014	-+-					19.18	[17.49; 21.04	5.7%
Wallace 2016	i	-				59.89	[46.09; 77.83	5.5%
Robinson 2010	+					13.28	[12.12; 14.55	5.7%
Cedarbaum 2013	+	-				24.42	[19.97; 29.86	5.6%
Riley 2013	+					19.34	[13.26; 28.20	] 5.3%
Wagner 2013	+					15.71	[11.73; 21.04	] 5.4%
Calvo 2014 👘						7.77	[ 6.70; 9.02	2] 5.7%
Al-Tayyib 2015 [a]	+					21.37	[17.97; 25.41	] 5.6%
Bluthenthal 2016			+			55.53	[48.74; 63.26	6] 5.7%
Hunter 2016	+					32.51	[26.50; 39.88	5.6%
Carlson 2017	i			•		71.11	[57.12; 88.53	5.6%
Latkin 2017						35.13	[29.16; 42.31	] 5.6%
Rosenthal 2018	-+					24.83	[14.10; 43.72	2] 4.7%
Oh 2018		-	•			50.87	[44.74; 57.84	] 5.7%
O'Rourke 2018					<u> </u>	87.40	[74.96; 101.90	] 5.7%
Random effects model	$\leq$	>_		1		27.79	[20.68; 37.35	] 100.0%
	20	40	60	80	100			

Figure 4.1. Random-Effects Meta-Analysis of North American Non-Fatal Overdose Rates Per 100 PY

Appendix 5. Country Specific Forest Plots




Figure 5.1. Random-Effects Meta-Analysis of Australian Non-Fatal Overdose Rates Per 100 PY




Figure 5.2. Random-Effects Meta-Analysis of Canadian Non-Fatal Overdose Rates Per 100 PY




Figure 5.3. Random-Effects Meta-Analysis of United States Non-Fatal Overdose Rates Per 100 PY

Author/Publication Year	Country	<b>Included Data Source</b>	<b>Data Collection Years</b>	N*	PY Contributed*	Non-Fatal Events*	Fatal Events*
Geddes et al. 2018	Australia	Iversen et al. 2017 VIDUS and ACCESS Data;	2014	848	848	211	
Caudarella et al. 2016	Canada	Kennedy et al. 2019	1996-2011	2317	14996; 1499	1795	134
Escudero et al. 2016	Canada	VIDUS and ACCESS Data	2006-2013	1760	7535	649	
Fairbairn et al. 2016	Canada	VIDUS Data	2005-2012	1114	557	79	
Hayashi et al. 2016	Canada	Kennedy et al. 2019	1996-2011	2317	14904.6		120
Hayashi et al. 2017	Canada	Kennedy et al. 2019	1996-2014	961	6456.52		57
Hayashi et al. 2018	Canada	Uhlmann et al. 2014	2016	669	334.5	85	
Ickowicz et al. 2017	Canada	ACCESS Data	2005-2014	626	313	40	
ckowicz et al. 2020	Canada	VIDUS and ACCESS Data	2003-2017	793	396.5	86	
Lake et al. 2015 [a]	Canada	VIDUS and ACCESS Data	2005-2014	1660	5343	670	
Lake et al. 2015 [b]	Canada	VIDUS and ACCESS Data	2005-2013	1697	4736	570	
Lake et al. 2015 [c]	Canada	VIDUS and ACCESS Data	2005-2013	1614	4724	558	
McCrae et al. 2020	Canada	VIDUS and ACCESS Data	2018	793	396.5	128	
Pedersen et al. 2016	Canada	VIDUS Data	2005-2014	1119	559.5	91	
Prangnell et al. 2019	Canada	VIDUS and ACCESS Data	2012-2016	327	163.5	47	
Fucker et al. 2015	Canada	VIDUS and ACCESS Data	2005-2013	1911	955.5	133	
Fucker et al. 2016	Canada	VIDUS and ACCESS Data	1996-2013	2806	1403	377	
Rafful et al. 2015	Mexico United States &	Rafful et al. 2018	2013	366	183	29	
Meacham et al. 2018	Mexico	West et al. 2020	2011-2012	735	367.5	74	
Allen et al. 2019	United States	O'Rourke et al. 2019	2018	371	185.5	162	
Al-Tayyib et al. 2017 [b]	United States	Al-Tayyib et al. 2017 [a]	2015	592	592	129	
Park et al. 2018	United States	Hunter et al. 2018	2016	203	203	63	
Гobin et al. 2018	United States	Latkin et al. 2019	2016-2017	218	218	76	
Wagner et al. 2014	United States	Wagner et al. 2015	2012-2013	480	240	39	

#### Appendix 6. Non-Analyzed Data Summary Table (N=24)

Person-Years (PY)

Vancouver Injection Drug Users Study (VIDUS)

AIDS Care Cohort to Evaluate Exposure to Survival Services (ACCESS)

\* Data was excluded from the meta-analysis